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Within the United States (U.S.), one-third of those who use cannabis (the most commonly used 
illicit drug in the U.S.), exhibit cannabis use problems significant enough to warrant a diagnosis of cannabis 
use disorder (CUD; Compton, Grant, Colliver, Glantz, & Stinson, 2004). Data suggests that quitting 
cannabis is highly difficult (Copersino et al., 2006), yet, there is little empirical knowledge about the nature 
of factors that relate to quit processes (e.g., self-efficacy). One potentially promising variable of relevance 
to CUD is distress intolerance (Leyro, Zvolensky, & Bernstein, 2010). Distress intolerance is referred to as 
(a) the perceived capacity to withstand negative emotional and/or aversive states, and (b) the behavioral act 
of withstanding distressing internal states elicited by some type of stressor. Although theoretically nested 
within a broader network of risk and protective processes, distress intolerance is posited to be related to, 
though conceptually distinct from, other variables (e.g., anxiety sensitivity; emotion regulation; Leyro et 
al., 2010). Individuals with higher levels of distress intolerance may be prone to maladaptively respond to 
distress (e.g., life stressors), and attempt to avoid negative emotions and/or aversive states (e.g., use 
cannabis to alter the perception or impact of negative mood, or to enhance positive mood). In contrast, 
persons with lower levels of distress intolerance may be more able to adaptively respond to distress (e.g., 
seek out alternative, more adaptive coping strategies instead of using cannabis).  
 
There is limited knowledge of the explanatory role of the inability to tolerate negative affect and 
other aversive internal sensations (e.g., withdrawal) in terms of CUD and the nature of the quit experience 
(e.g., beliefs about barriers to quitting). The aim of the present study was to examine the main and 
interactive effects of perceived and behavioral indices of distress intolerance in terms of cannabis quit-
related variables, including (a) failed quit attempts, and duration of average time to relapse for past quit 
attempts; (b) greater severity of withdrawal symptoms experienced while quitting in the past, lower self-
efficacy for abstaining, and greater perceived barriers for quitting cannabis; and (c) greater CUD problems. 
The sample recruited was characterized by  racially and ethnically diverse (65.2% minority) adult cannabis 
users, many of whom had not completed college (46.5%). The sample had high rates of co-occuring 
psychiatric and medical illness (e.g., 36.1% had a current anxiety disorder, 26.4% had a current mood 
disorder, and half endorsed a medical condition), and over 25% fell below the 2013 Federal Poverty Level. 
 
There was no empirical support for an interactive or main effect of perceived or behavioral 
distress intolerance for any of the dependent variables. Although previous studies did not employ most of 
the cannabis dependent measures utilized in the current report, the lack of significant effects in the 
regression models was surprising given previous work on the topic (focused largely on coping motives for 
cannabis use). At the bi-variate level, there was some modest evidence of a 'signal' for perceived distress 
intolerance for certain cannabis dependent variables; these effects ranged from small to moderate. These 
data suggest, at least among the present largely minority sample, neither perceived or behavioral distress 
intolerance are robustly related to the cannabis dependent measures. One conservative interpretation of 
these findings is that distress intolerance may not perform the same across all CUD samples.  
 
Post hoc analyses focused on perceived distress intolerance subfactors relations to the dependent 
variables; indirect explanatory role of negative affect in perceived distress intolerance-cannabis relations; 
and bi-variate relations between perceived and behavioral distress intolerance with other transdiagnostic 
distress processes. Results suggested (a) no incremental explanatory effect for specific perceived distress 
intolerance subfactors; (b) a significant indirect effect of negative affect in the relation between perceived 
distress intolerance and certain cannabis dependent variables; and (c) consistent evidence of convergent 
validity for perceived distress intolerance with other transdiagnostic affective vulnerability factors. I 
contextualize the findings in relation to past work, and the methodology employed in the current study. I 
discuss how future theory-driven work that seeks to uncover the time course and patterning between 
distress intolerance, negative mood, and cannabis use behavior are needed. I also suggest that this work will 
likely have the greatest impact when the social contexts of CUD populations (e.g.,  social determinants of 
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CHAPTER 1: CANNABIS USE AND ITS DISORDERS 
1.1. Developmental Stages, Prevalence, and Negative Impact 
Until relatively recently, cannabis abuse was defined as a pattern of cannabis use that includes 
significant and unpleasant consequences associated with frequent cannabis use. This pattern of use needs to 
have occurred within a 12-month period. Examples of consequences associated with cannabis abuse 
include legal problems, repeated use in physically hazardous situations, and repeated social and 
interpersonal problems as a result of use. A central differentiating feature of cannabis abuse and 
dependence was that abuse only includes harmful consequences of frequent use, rather than compulsive 
use, tolerance, and perhaps withdrawal (APA, 1994). It also is important to note that abuse could not be 
diagnosed if cannabis dependence criteria had been met. This distinction highlights the more severe nature 
of cannabis dependence from a historical perspective. In the relapse stage, individuals who have attempted 
to stop using return to their cannabis use behavior after a period of sustained abstinence.  
In 2013, cannabis-related disorders were revised by the American Psychiatric Association (2013) 
with the publication of the Diagnostic and Statistical Manual for Mental Disorder, 5th Edition in an effort to 
enhance classification, consistency, and clarity of substance use disorders. Of these changes, cannabis 
abuse and cannabis dependence were collapsed into one diagnostic category: Cannabis Use Disorder 
(CUD), defined as a pattern of problematic use of cannabis, which leads to impairment or distress, often 
involving recurrent use, unsuccessful cessation, craving, tolerance, and withdrawal (APA, 2013). Other 
substantive changes included the removal of recurrent legal problems among the diagnostic criteria, and the 
addition of cannabis withdrawal (APA, 2013).  
1.1.1. Developmental Stages 
Developmental stages of cannabis use are central to understanding the nature of CUD. One well-
known and broadly used approach is that offered by Flay (1993). Flay’s (1993) stage model (originally 
from work on tobacco) suggests substance use follows a generally well-specified sequence of behavior that 
includes the following stages: initiation, maintenance, and relapse. In this model, the initiation stage 
reflects trying cannabis on the initial few trials and further experimentation (irregular use over time). The 
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maintenance stage includes regular use of cannabis (ranging from weekly to daily use); it is in this stage 
that individuals are most apt to develop CUD. 
1.1.2. Prevalence 
Cannabis has been the most widely used illicit substance for 40 consecutive years in the United 
States (U.S.; Johnston, O'Malley, Bachman, & Schulenberg, 2013), with approximately 25 million people 
in the U.S. (8.6% of the population) having used cannabis in the past year (Johnston, O’Malley, Bachman, 
& Schulenberg, 2005), and approximately 18.9 million people in the U.S. (6.1% of the population) having 
used cannabis in the past month (NIDA, 2012),. Cannabis can be consumed by ingestion, smoking, or 
vaporization. There are at least 60 different cannabinoids, although the pharmacokinetics of the vast 
majority of these compounds are still being actively explored (Ashton, 1999). Of these, the most well 
known cannabinoid is tetrahydrocannabinol (THC). THC is believed to be the most potent psychoactive 
agent in the cannabinoid plant (Tanda & Goldberg, 2003). Cannabinoids are believed to have evolved due 
to their influence on mood and behavior (e.g., influence pain perception; Tanda & Goldberg, 2003). For 
example, there are numerous reports that cannabinoids may dampen or modulate pain responsivity and 
decrease somatic distress (e.g., stomach irritation; Tanda & Goldberg, 2003). Other reports suggest that 
cannabinoids may have a dose-dependent response in relation to anxiety (Machoulam & Parker, 2012). For 
example, lower doses may have anxiolytic properties, whereas higher doses may provoke an anxiogenic 
response (Rubino et al., 2008). 
An estimated 8% of persons who have ever used cannabis will become daily users (Lopez-
Quintero et al., 2011; Wagner & Anthony, 2002). According to SAMHSA’s National Survey on Drug Use 
and Health, 7.5% of the population can be identified as current (“past month”) cannabis users, making 
cannabis the most used (illicit) drug in the U.S. (2014). Lifetime cannabis dependence is estimated at 8.5% 
of the general population (Compton, Thomas, Stinson, & Grant, 2007). In 2012, NIDA reported that 4.3 
million Americans met clinical criteria for dependence or abuse, which is more than twice the amount of 
individuals who meet dependence/abuse for prescription pain relievers (2.1 million) and four times the 
number for cocaine dependence/abuse (1.1 million). Rates of conditional dependence, defined as the risk 
for developing dependence among those who have ever used the drug, indicate that cannabis is associated 
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with a high rate of dependence potential (Anthony, Warner, & Kessler, 1994). For example, the relative 
risk of experiencing cannabis dependence given use of the drug in the past year is estimated to be 2% 
among adults, which is only slightly lower than that for cocaine (7.1%) and comparable to rates observed 
for alcohol (2%; Lopez-Quintero et al., 2011). Furthermore, greater levels of use are related to an increased 
risk for dependence. The rate of dependence appears to be  approximately 17-18.8% among those persons 
using cannabis on a regular basis (weekly or daily, respectively; Cougle, Hakes, Macatee, Zvolensky, & 
Chavarria, in press). Moreover, some work has suggested cannabis use problems have increased, with 35% 
of adult cannabis users in the U.S. currently meeting criteria for CUD compared with 30% 10 years earlier, 
representing an increase of approximately 730,000 individuals (Compton et al., 2004; Cougle et al., in 
press).  
Treatment and community studies have examined prevalence rates of cannabis use among samples 
suffering from a variety of medical and psychological problems. For example, one study found that among 
those seeking treatment for psychosis, approximately 23% currently used cannabis, with about half of that 
group currently “misusing” the drug (Hambrecht & Hafner, 2000). Another community-based study found 
that approximately 16% of those with spinal cord injury used cannabis (Young, Rintala, Rossi, Hart, & 
Fuhrer, 1995). Other work has reported that cannabis use accounted for as much as 25% of the primary 
drug problems of individuals seeking residential drug treatment (Fligiel et al., 1997). These studies 
collectively suggest that cannabis use: (1) may be overrepresented among certain “vulnerable” populations 
and (2) is a primary clinical and public health concern. 
1.1.3. Impact 
 Historically, cannabis has been viewed by some as a ‘less severe’ substance use problem 
(Stephens, 1999). Although cannabis use has probably evolved due to its influence on mood and behavior 
(e.g., decrease sensitivity and reactivity to pain; Bonn-Miller, Boden, Bucossi, & Babson, 2014; Lee et al., 
2013), there are a number of negative correlates related to excessive use. Scientific study has, in fact, 
provided empirical evidence that CUD is associated with a number of clinically significant problems 
(Kalant, Corrigall, Hall, & Smart, 1999). Indeed, there are several empirically documented negative 
consequences of frequent or problematic cannabis use (typically defined as weekly or daily use), such as 
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increased risk of severe medical disease (e.g., Bloom, Kaltenborn, Paoletti, Camilli, & Lebowitz, 1987), 
myocardial infarction (Mittleman, Lewis, Maclure, Sherwood, & Muller, 2001), increased risk taking 
behavior (e.g., unprotected sexual intercourse; McDonald, Schleifer, Richards, & de Wit, 2003; Sussman, 
Stacy, Dent, Simon, & Johnson, 1996), and clinically-relevant life impairment (e.g., Cougle, Hakes, 
Macatee, Chavarria, & Zvolensky, in press; Leirer, Yesavage, & Morrow, 1991; Zimmerman & Schmeelk-
Cone, 2003). Classic work by Lynskey and Hall (2000), for example, indicates that weekly cannabis use is 
related to decreased educational attainment, and others have found that weekly cannabis use is associated 
with reduced workplace productivity (Lehman & Simpson, 1992), as well as impaired occupational 
judgment (e.g., Leirer et al., 1991). Notably, studies have found that greater weekly use of cannabis is 
associated with increased risk of severe respiratory illnesses, particularly chronic bronchitis (Fligiel et 
al.,1997). Additionally, cannabis use has been linked to fatal traffic accidents and general driving 
impairment (Everest, Tunbridge, & Widdop, 1989) after controlling for the variance accounted for by 
concurrent alcohol and other substance use (Gjerde & Kinn, 1991). Data from the Drug Alert Warning 
Network (DAWN) indicates that cannabis also is the most commonly mentioned substance in emergency 
department admissions among youth (ages 12-17), the second most common for young adults (ages 18-24), 
and the third most for adults over age 25 (OAS, 2001).  
 Several lines of research have documented the co-occurring nature of negative affective states and 
problematic cannabis use. In one recent study, anxiety symptoms were associated with the self-reported 
quantity of cannabis used and cannabis-associated problems (Van Dam, Bedi, & Earleywine, 2012). 
Similarly, other research has suggested that heavy cannabis users report higher levels of somatization, 
anxiety, paranoid ideation, and psychoticism (reported via Symptom Checklist [SCL-90-R; Derogatis, 
1992]; Somaini et al., 2012). Although CUD may be related to multiple forms of psychopathology, there 
appear to be specific sub-groups of emotionally vulnerable persons who may be at particularly heightened 
risk for cannabis-related problems. As one illustrative example, nearly one-third to one-fourth of people 
with cannabis dependence have social anxiety disorder (SAD), a higher rate than that reported for other 
anxiety and mood disorders (Agosti, Nunes, & Levin, 2002; Stinson, Ruan, Pickering, & Grant, 2006). 
After controlling for gender, some work suggests adolescents with SAD are almost seven times more likely 
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to develop cannabis dependence in early adulthood (Buckner et al., 2008). Other work indicates elevated 
social anxiety symptoms are associated with greater cannabis-related problems across a range of 
populations (Buckner, Bonn-Miller, Zvolensky, & Schmidt, 2007; Buckner, Heimberg, Matthews, & 
Silgado, 2012; Buckner, Heimberg, & Schmidt, 2011; Buckner, Mallott, Schmidt, & Taylor, 2006; Buckner 
& Schmidt, 2008; Buckner, Schmidt, Bobadilla, & Taylor, 2006; Buckner, Zvolensky, & Schmidt, 2012). 
1.2. Motivation to Quit, Reasons for Quitting, and Success in Quitting 
1.2.1. Motivation to Quit  
Empirical evidence indicates that a large number of individuals who use cannabis on a regular 
basis are indeed motivated to quit. The first body of literature has evaluated treatment-seeking behavior. 
Here, the Drug Abuse Reporting Program (Sells, 1974) and other reports (Simpson, Savage, & Sells, 1978) 
first documented decades ago that a clinically significant number of individuals seek therapeutic services 
for 'problematic' cannabis use. Other large-scale surveys independently replicated such findings (Gerstein, 
& Johnson, 1999; Hubbard et al., 1989). Dennis et al.  (2002), for example, reported that of “the 1.5 million 
adult admissions to the U.S. public treatment system in 1998, 35% were admitted for treatment of cannabis 
problems (p. 9).” Such rates are higher than those found for cocaine (32%), opioids, (18%), stimulants 
(9%), and other psychoactive substances (12%; Dennis, Babor, Roebuck, & Donaldson, 2002). 
Additionally, other reports involving national (representative samples) databases have found that demand 
for treatment of cannabis use and its disorders doubled between 1992 and 1998 (SAMHSA, 2001). It also is 
important to note cannabis treatment outcome studies have documented that a large number of treatment-
seeking cannabis users are not current polysubstance abusers (Stephens, 1999; Stephens, Roffman, & 
Curtin, 2000). For example, Stephens et al. (1993) found that 80% of a large, cannabis dependent sample (n 
= 309) did not report abuse of other substances in the past 90 days and 40% reported never abusing a drug 
other than cannabis. These data indicate cannabis represents a significant clinical and public health problem 
in its own right and commonly prompts treatment-seeking behavior even in the absence of other drug use.  
Another body of empirical evidence related to the 'motivation to quit' suggests that, despite the 
notable rates of documented treatment-seeking behavior, most persons using cannabis actually attempt to 
quit on their own (i.e., without seeking professional assistance; Copersino et al., 2006; Cunningham, 2000; 
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Weiner, Sussman, McCullar, & Lichtman, 1999). Such self-quit rates are generally similar to those 
observed for other substances (e.g., tobacco; Hughes et al., 1996; Lopez-Quintero et al., 2011). In fact, 
numerous studies have reported that by young adulthood, many individuals have made multiple cannabis 
quit attempts on their own. For example, studies of weekly cannabis users have indicated that by age 30, 
individuals have reported a range of three to seven quit attempts on their own (e.g., Copersino et al., 2006; 
Stephens et al., 1993). Although these 'unsuccessful quitters' may presumably ultimately seek professional 
treatment when they continue to fail in their quit efforts, it is not presently clear what percentage will 
ultimately do so and under what circumstances.   
The aforementioned quit data are noteworthy in the context of the present study for at least two 
reasons. First, these data suggest that a large proportion of those with CUD are interested in and pursue 
quitting with and without professional assistance. Second, there is relatively still little empirical knowledge 
about the mechanisms underlying success or failure in quit attempts, leaving a major gap in clinically-
relevant knowledge.  
1.2.2. Reasons for Quitting 
Current cannabis users, ranging from monthly users to those with CUD, report multiple, 
concurrent reasons for quitting, and that such reasons tend to vary as a function of age, gender,  race, and 
time (Chauchard, Levin, Copersino, Heishman, & Gorelick, 2013; Copersino et al., 2010; Goodstadt, 
Sheppard, & Chan, 1984; Martin, Duncan, & Zunich, 1983; Stephens, Wertz, & Roffman, 1993; Weiner et 
al., 1999). Among youth, legal and parental problems tend to be the most common reasons for quitting, but 
among adults, worry about physical and psychological effects of cannabis use is the most often cited factor 
for wanting to quit (Copersino et al., 2010; Martin et al., 1983; Weiner et al., 1999). For example, 
Copersinio et al. (2006) reported that 60% of non-treatment seeking adult weekly cannabis users reported 
worry about health problems (both real and perceived) as a motivating factor for quitting, and 63% desired 
to quit in order to gain more ‘self-control’ over their lives. In another study, Reilly and colleagues (1998) 
similarly found that anxiety or depressive symptoms were the most commonly reported ‘negative effects’ 
of cannabis use and the primary reason for quitting among weekly cannabis users (n = 268). Others have 
reported similar findings among both non-treatment seekers (Boyd et al., 2005) and treatment seekers 
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(Stephens et al., 1993); such findings do not appear to vary as a function of type of cannabis use pattern or 
problem (Boyd et al., 2005). Overall, available data suggest cannabis users typically express multiple 
reasons for quitting, with the most common and consistently reported reasons pertaining to excessive 
negative emotional symptoms (e.g., anxiety and depression) and impaired levels of personal self-control.  
1.2.3. Success in Quitting 
Individuals attempting to quit cannabis experience marked difficulty whether they make a quit 
attempt on their own or seek professional (formal) treatment. Numerous survey studies, for example, have 
documented that current cannabis users, both who are and are not dependent on the drug, who try to quit on 
their own report difficulty in remaining abstinent and frequently fail in their efforts to remain abstinent, as 
indexed by their numerous quit attempts (Copersinio et al., 2006; Weiner et al., 1999). Although self-quit 
attempts without professional assistance tend to be the most frequently employed quit strategy (Boyd et al., 
2005; Budney, Vandrey, Hughes, Thostenson, & Bursac, 2008), it is striking that, even among those who 
do seek professional treatment, relapse to use is a highly common experience. Indeed, in a critical review of 
the treatment outcome literature, McRae and colleagues (2003) concluded: “studies suggest that many 
patients do not show a positive treatment response, indicating that cannabis dependence is not easily treated 
(p. 369).” For example, one large-scale controlled study (n = 291) found that 63% of adults receiving two 
of the best available intervention strategies - motivational individualized intervention or cognitive-
behavioral therapy - relapsed to regular use within four months (Stephens et al., 2000). For comparison 
purposes, the delayed treatment (control) condition reported that 91% of individuals were not abstinent at 
the four-month assessment (Stephens et al., 2000). At 16 months, relapse rates among the active treatment 
conditions rose to 71% and 72% for the motivational individualized intervention and cognitive-behavioral 
therapy, respectively (Stephens et al., 2000).  
Other studies have reported similar results (Copeland, Swift, Roffman, & Stephens, 2001; 
Stephens, 1999; Stephens et al., 1993), and clinical trials have extended such work by noting that in 
addition to full relapse, lapses are highly common and clinically significant. For example, Moore and 
Budney (2003) reported that among cannabis dependent adult outpatients receiving treatment (n = 152), 
71% lapsed (defined as any cannabis use made during a quit attempt) within six months, 46% within three 
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months, and 24% within one month. In this same study, 71% of lapsers ultimately experienced a full 
relapse (defined as four or more days of use per week; Moore & Budney, 2003). These data make clear the 
challenge of quitting among individuals with CUD. 
1.3. Predictors of Cannabis Lapse and Relapse 
1.3.1. Substance Use, Stress, and Coping Factors 
There has been lesser scientific work focused on predictors of success or failure in attempts to quit 
using cannabis. The work that has been completed in this regard has been broadly guided to varying 
degrees by social learning (Bandura, 1997), stress and coping (Kaplan, 1996), and behavioral economic 
(Bickel & Vuchinich, 2000) theories of substance use and relapse (McClure, Stitzer, & Vandrey, 2012). 
These studies have thus far provided a number of initial and important observations: (1) early lapses are 
predictive of later relapses among adult and adolescent cannabis abuse or dependent persons, regardless of 
whether they receive formal treatment or not (Agosti & Levin, 2007; Harrison & Asche, 2001; Latimer, 
Winters, Stinchfield, & Traver, 2000; Moore & Budney, 2003); (2) personal stressors (e.g., family conflict) 
are related to increased odds of relapse among individuals with cannabis abuse or dependence receiving 
outpatient treatment (Godley, Kahn, Dennis, Godley, & Funk, 2005); (3) other substance use and peers’ 
substance use (alcohol and other drugs) are predictive of increased odds of relapse among adolescent 
cannabis abusing or dependent outpatients (Latimer et al., 2000); and (4) levels of personal self-efficacy 
(i.e., beliefs regarding one’s ability to refrain from use) for abstaining from cannabis use among adults with 
cannabis abuse or dependence seeking treatment is modestly predictive (Stephens, Wertz, & Roffman, 
1995). These data collectively indicate that substance use as well as stress and coping-related factors (e.g., 
self-efficacy) likely play an important role in cannabis relapse among adults and adolescents. These 
observations are consistent with findings from other areas of substance use disorder work (Leshner, 1999). 
1.3.2. Psychological Symptoms and Disorders 
Due partially to the observation that elevated psychiatric symptoms are often co-occuring among 
treatment-seeking cannabis users meeting criteria for abuse or dependence (Budney, Radonovich, Kiggins, 
& Wong, 1998; Stephens et al., 1993), studies have been conducted to ascertain whether psychological 
vulnerabilities, broadly defined as psychological risk factors or disorders, may be relevant to cannabis 
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relapse. This work is consistent with contemporary theories that posit persons with substance use disorders 
and co-occurring psychological vulnerabilities (e.g., high levels of negative affectivity or full-blown 
psychiatric disorders) are at risk for early lapse, and therefore, generally poorer treatment outcome (Brown, 
Lejuez, Kahler, Strong, & Zvolensky, 2005; Coambs, Kozlowski, & Ferrence, 1989; Hughes, 1993; Hughes 
& Brandon, 2003; Shiffman, 1993; Zvolensky & Bernstein, 2005). It is important to note from the outset 
that numerous studies have found that both treatment-seeking and non-treatment seeking individuals (adults 
and adolescents) meeting criteria for CUD generally have significantly higher rates of psychological 
symptoms and disorders relative to those not with CUD (Agosti et al.,, 2002; Arendt & Munk-Jorgensen, 
2004; Bovasso, 2001; Budney et al., 1998; Copeland et al., 2001; Cougle et al., in press; Miller, Klamen, 
Hoffmann, & Flaherty, 1996; Rey, Sawyer, Raphael, Patton, & Lynskey, 2002; Troisi, Pasini, Saracco, & 
Spalletta, 1998; Zvolensky Bernstein, et al., 2006). Moreover, time sampling studies on cannabis using 
samples suggests that negative mood is often an antecedant to cannabis use more generally (Buckner, 
Zvolensky, Crosby, Wonderlich, Ecker, & Richter, 2015).  
Contemporary theories of substance use relapse suggest such psychological factors, such as 
elevated negative emotional symptoms or disorders, could adversely impact success in quitting cannabis 
use. For example, co-occurring psychological problems may increase stressors as well as motivations to use 
cannabis to 'manage' dysregulated negative emotional states (e.g., coping-oriented motives; Zvolensky, 
Leen-Feldner, et al., 2006). In fact, some have argued that the management of aversive emotions may be 
centrally important to cessation success (Rooke, Norberg, & Copeland, 2011). Of the completed studies in 
this domain, as reviewed below, each has thus far focused on a relatively narrow band of psychological 
symptoms and disorders. Yet, the results of these investigations have converged on the same general 
conclusion: negative emotional and psychological symptoms are related to increased risk of cannabis 
relapse among current users. In one study, the presence of psychotic symptoms among psychotic disorder 
adult patients who were monthly cannabis users predicted cannabis relapse (Hides, Dawe, Kavanagh, & 
Young, 2006). In other studies, adolescents meeting criteria for cannabis abuse or dependence in outpatient 
psychiatric treatment were more apt to relapse to cannabis use if they had comorbid conduct disorder, 
depression, or attention deficit hyperactivity disorder (Grella, Hser, Joshi, & Rounds-Bryant, 2001; White 
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et al., 2004). Arendt and colleagues (2007) explored medical charts over time of 3,114 adult participants 
who received treatment for cannabis dependence in Denmark. Results indicated that cannabis dependent 
persons’ psychiatric treatment for problems not related to substance use (i.e., other mental health problems) 
was prospectively associated with an increased risk of future re-entry into treatment for cannabis use.  
Notably, other emerging research has focused on other factors that predict  cessation outcome 
(Pacek & Vandrey, 2014). Here, differences in sociodemographic charecteristics have also been noted, 
including race (identifying as African American), gender (males), and marital status (unmarried) being 




 Collectively, there is evidence that psychological symptoms (most notably, negative affect) and 
disorders as well as other sociodemographic variables are related to the maintenance of cannabis as well as 
relapse. Therefore, it appears that there is a need for a more integrative focus on individual difference 
factors for stress responsivity and psychological vulnerability in an effort to gain a more comprehensive 
understanding of lapse and relapse processes for CUD. 
 11 
 
CHAPTER 2: DISTRESS INTOLERANCE: CONCEPTUALIZATION AND OPERATIONAL 
DEFINITION, MEASUREMENT AND RELATION TO PSYCHOPATHOLOGY 
2.1. Conceptualization and Operational Definitions 
One 'stress responsivity factor' of potential relevance to CUD is distress intolerance (Leyro et al., 2010; 
Zvolensky, Bernstein, & Vujanovic, 2011; Zvolensky & Otto, 2007; Zvolensky, Vujanovic, Bernstein, & 
Leyro, 2010). Distress intolerance reflects an individual’s perceived or behavioral capacity to withstand 
experiential/subjective distress related to affective, cognitive, and/or physical states (e.g., negative affect, 
physical discomfort; Simons & Gaher, 2005; Zvolensky et al., 2011). Scholars have  suggested it is a 
transdiagostic  individual difference factor for stress responsivity and psychological vulnerability (Linehan, 
1993; McHugh & Otto (2011). Conceptual models of perceived distress intolerance suggest that the 
construct is hierarchical in nature (Zvolensky et al., 2010). Namely, there is a global “experiential distress 
intolerance” construct supported by other, specific lower-order constructs (e.g., frustration intolerance, 
depressed mood intolerance (see Figure 1). In fact, consistent with the five-factor model of Zvolensky et al. 
(2010), independently conducted empirical work supports this type of hierarchical perceived distress 
intolerance model (Bardeen, Fergus, & Orcutt, 2013). Although distress intolerance is presumably related 
to other emotion vulnerability processes such as anxiety sensitivity, emotion dysregulation, withdrawal 






















Figure 1: Heuristic depiction of the global experiential distress (in)tolerance construct and lower-
order, domain-specific dimensions (Zvolensky et al., 2010) 
 
2.1.1. Measurement 
Distress intolerance has been characterized by two dominant conceptual and related measurement 
perspectives. Specifically, distress intolerance has been studied as: (a) the perceived capacity to withstand 
aversive emotional or physical states (assessed via self-report measures; e.g., Distress Tolerance Scale 
[DTS; Simons & Gaher, 2005], Discomfort Intolerance Scale [DIS; Schmidt, Richey, & Fitzpatrick, 2006], 
and (b) the behavioral act(s) of withstanding distressing internal states elicited by some type of stressor 
(assessed via the latency to discontinue distressing tasks; e.g., mirror-tracing task, breath-holding task; 
Zvolensky et al., 2011). Accordingly, there have been two methodological literatures, each linked to one of 
these conceptual perspectives on distress intolerance.  
There are numerous self-report measurements of distress intolerance measuring  perceived 
capacity to withstand negative emotions. First, tolerance of ambiguity, which reflects the way an individual 
processes information about a situation when faced with vague, unfamiliar or complicated stimuli (TOA; 
Frenkel-Brunswik, 1948, 1951, 1959; Hoffeditz & Guilford, 1935; Furnham & Ribchester, 1995), has 
spanned several disciplines, such as management and organizational psychology (Herman, Stevens, Bird, 
Mendenhall, & Oddou, 2010). TOA, or the perceived capacity to tolerate threatening stimuli, is 







































Intolerance of uncertainty (IU), which reflects the different emotional, cognitive, or behavioral 
responses people demonstrate when presented with uncertain situations and events (IU; Buhr & Dugas, 
2002; Dugas, Buhr, & Ladouceur, 2004), is thought of as distinct from TOA, in that, IU reflects fear or 
uncertaintly about events that have not yet happened, therefore serves to maintain or excerabte perceived 
threat (Carleton, Gosslin, & Asmundson, 2010). 
 Discomfort intolerance, defined as the capacity to withstand uncomfortable physical sensations 
(DIS; Schmidt et al., 2006), is theorized to capture an individual’s capacity to withstand aversive and 
uncomfortable physical or bodily states, and has been implicated in the development of anxiety 
psychopathology, such as fear of bodily sensations and hyper-arousal (Schmidt et al.,2006).  
Distress intolerance, defined as an individual’s perceived ability to withstand negative emotional 
states (DT; Simons & Gaher, 2005), has been described as, “one’s evaluations and expectations of 
experiencing negative emotional states in respect to (1) tolerability and aversiveness, (2) appraisal and 
acceptability, (3) tendency to absorb attention and disrupt functioning, and (4) regulation of emotions, 
specifically, the subsequent strength of action tendencies to either avoid or immediately attenuate the 
experience (Simons, & Gaher, 2006).”  Frustration intolerance, denoting an individual’s beliefs regarding 
uncertainty, controllability, and aversiveness of emotions, has been connected to procrastination and 
irrational beliefs related to the demand that “reality should be what one wishes it be (Harrington, 2005)”.  
There also are a variety of behavioral distress intolerance measures, such as (1) physical tolerance 
tasks, measured in a variety of ways, capturing an individual’s ability to withstand exposure to a specific 
type of aversive stimulus (e.g., breath-holding duration; Asmundson & Stein, 1994) and (2) cognitive-based 
tolerance tasks, also measured in a variety of ways, capturing an individual’s ability to complete difficult 
and frustrating tasks which often require cognitive resources (e.g., mirror-tracing task; Strong et al., 2003). 
2.1.2. Interrelations between Self-Report and Behavioral Distress Intolerance Indices 
McHugh and colleagues (2011) reported perceived distress intolerance measures and self-report 
measures of related constructs (e.g., anxiety sensitivity) were highly correlated, as were certain behavioral 
distress intolerance measures. However, behavioral and self-report measures (as classes) did not exhibit 
significant associations with one another (McHugh et al., 2011). Similarily, Bernstein, Marshall-Berenz, 
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and Zvolensky (2011) have reported perceived distress intolerance measures were significantly related to 
one another and the behavioral distress intolerance measures were significantly related to one another, 
although the self-report and behavioral measures were orthogonal to one another. Since these initital 
studies, the same patterns of findings (within class associations) have been replicated and extended to 
numerous populations (e.g., Ameral, Palm Reed, Cameron, & Armstrong, 2014; Anestis et al., 2012; Ellis, 
Vanderlind, & Beevers, 2013; Oser,Trafton, Lejuez, & Bonn-Miller, 2013).  
Existing data suggest that perceived and behavioral distress intolerance indices may possibly not 
necessarily reflect individual differences of a common latent distress intolerance variable. Such results are 
in line with the perspective that the distress intolerance literature, as a whole, may be advanced by 
recognizing the distinction between self-report and behavioral tolerance constructs (Leyro et al., 2010). For 
example, it may be fruitful to conceptualize perceived distress intolerance as related to antecedent emotion 
regulation (i.e., expectancies that effect emotional or self-regulatory processes); and behavioral acts of 
tolerance as related to response-focused emotion regulation in the context of or following the onset of 
experiential distress (i.e., responses directed at an ongoing emotional response; Bernstein et al., 2011). This 
type of approach inherently integrates theory and empirical knowledge of the nature of emotional 
processing and regulation with distress intolerance (Bernstein et al., 2011; Webb, Miles, & Sheeran, 2012). 
2.1.3. Relations to Psychological Symptoms and Disorders 
As reflected in the above perspective on distress intolerance, this construct may theoretically be 
related to aversive emotional states and may be followed by psychological or behavioral attempts to reduce 
the distress experienced (Simons & Gaher, 2005). In other words, intolerance of aversive somatic or 
affective states may amplify awareness of distress, and consequently, strengthen avoidant coping (negative 
reinforcement learning; McHugh & Otto, 2012). Accordingly, individuals with higher levels of distress 
intolerance may be more prone to maladaptively respond to distress and distress-eliciting contexts.  
Consistent with this type of perspective, distress intolerance is related to a variety of 
psychopathological symptoms and disorders (Leyro et al., 2010). For example, higher levels of perceived 
distress intolerance for negative emotional and physical stimuli are significantly related to an increased risk 
of a variety of negative emotional symptoms (Asmundson & Stein, 1994; Boelen & Reijntjes, 2009; Telch, 
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Jacquin, Smits, & Powers, 2003; Timpano, Buckner, Richey, Murphy, & Schmidt, 2009). Other work has 
similarly begun to link distress intolerance to specific mood and anxiety (e.g., Schmidt, Mitchell, Keough, 
& Riccardi, 2011) disorders and depression (Gorka, Ali, & Daughters, 2012; Tull and Gratz, 2013; 
Williams, Thompson, & Andrews, 2013). Furthermore, higher levels of behavioral intolerance for acute 
episodes of aversive states are related to substance use relapse (Brown et al., 2002), as well as eating 
psychopathology (e.g., binging/purging; Anestis, Selby, Fink, & Joiner, 2007; Lavender et al., 2015), and 
psychotic spectrum disorders (Nugent et al., 2014). Perhaps not surprisingly, attempting to decrease distress 
intolerance has become a major feature of many evidence-based psychosocial treatment programs for mood 
and anxiety disorders, especially those that have a transdiagnostic orientation or focus (e.g., Barlow, Allen, 
& Choate, 2004; Linehan, 1993; Otto, Powers, & Fischmann, 2005; Tull, Schulzinger, Schmidt, Zvolensky, 
& Lejuez, 2007). Moreover, distress intolerance has been found to be an explanatory process in substance 
use treatment (Bornovalova et al., 2012; Hsu, Collins, & Marlatt, 2013). Notably, a growing body of work 
has linked distress intolerance to physical illness and disease progression (Magidson et al., 2013; Oser, 
Trafton, Lejuez, & Bonn-Miller, 2013). 
2.2. Distress Intolerance and Cannabis Use Behavior 
Currently, there are a highly limited number of studies examining distress intolerance and CUD or 
cannabis use more generally. In this next section of the document, I review relevant studies in this domain. 
See Table 1.  
Daughters et al. (2005) first explored the relation between distress intolerance and duration of 
most recent abstinence attempt. Participants were included if they endorsed use of cannabis, alcohol, 
stimulants, sedatives, opiates, hallucinogens, PCP, or inhalants prior to entering substance treatment. A 
mental arithmetic task (Paced Auditory Serial Addiction Task [PASAT]; Gronwall, 1977) was 
administered, while participant’s persistence on the task was measured as an index of distress intolerance. 
Participants (n = 89) were enrolled in a residential substance abuse treatment facility in Washington, DC, 
with a mean age of 39.2 (SD = 9.4) years, 62.9% male, 89.9% identifying as African American and 
educational backgrounds ranging from not completing high school/received GED (34.8%) to completing 
high school (42.7%) or attending some college or technical school (22.5%; Daughters et al., 2005). After a 
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detailed description of the study was given, and informed consent was collected, participants were 
instructed that they would be paid between $5 and $15 at the end of the session dependent on their total 
score obtained from participation in the task, providing incentive indirectly related to persistence of 
completing the task (Daughters et al., 2005). Results suggested that duration of substance abstinence is 
related to persistence on the distress intolerance task after controlling for demographics, level of substance 
use, negative affectivity, and skill/performance on the task (Daughters et al., 2005). As this study involved 
poly-substance using treatment seekers, the generalizability to cannabis users per se is not known. 
Moreoever, distress intolerance was measured using only persistence on the PASAT with a monatary 
reward. Thus, it is unclear if the distress intolerance index was more a measure of task persistence than 
distress intolerance (Leyro et al., 2010).  
In other research, Simons and Gaher (2005) conducted a study (n = 642) to develop the DTS 
(Simons &  Gaher, 2005). Participants were recruited from two state universities (70% female; Mage = 
19.90, SD = 1.64) with 89% identifying as Caucasian, 7% identifying as African American, 1% identifying 
as Asian, 1% identifying as multiracial, and 2% identifying as other (Simons & Gaher, 2005). Prior to 
participation, informed consent was obtained; research subjects were then asked to complete an internet-
based assessment (Simons & Gaher, 2005). A factor analysis was conducted on the 16-items of the DTS, 
with results indicating the exclusion of two items; thereafter, a subsequent factor analysis was run on the 
remaining 14 items, finding support for a single factor solution, which accounted for 88% of the overall 
variance. In the validation aspect of the study, perceived distress intolerance, as measured by the DTS total 
score, was negatively related to both alcohol and cannabis coping motives (Simons & Gaher, 2005). These 
findings suggest that those who endorse high levels of perceived distress intolerance have an increased 
concurrent likelihood to endorse using these substances (alcohol and cannabis) because they believe it can 
help reduce negative affect (Simons & Gaher, 2005). The study results are perhaps most relevant to the 
maintenance phase of cannabis use. However, it is unclear how well these findings generalize to more 
severe cannabis users or if similar patterns of results would be evident for alternative measurement 
approaches for distress intolerance. 
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 In another study, Buckner, Keough, and Schmidt (2007) aimed to clarify the relation between 
substance use (alcohol and cannabis) and depression by exploring individual differences of discomfort 
(Discomfort Intolerance Scale [DIS]; Schmidt et al., 2006) and perceived distress intolerance (Distress 
Tolerance Scale [DTS]; Simons and Gaher, 2005). The study sample was predominantly Caucasian 
(78.1%) and consisted of 265 undergraduate psychology students (63.3% female; Mage = 18.7 (SD = 1.2), 
with 74% reporting alcohol use in the past month, 60% reporting lifetime cannabis use, 31.3% reporting 
cannabis use in the past month, and 8.2% reporting daily cannabis use (Buckner et al., 2007). Results 
indicated that perceived distress intolerance, as measured by the DTS, was significantly associated with 
increased problems associated with alcohol and cannabis use, as well as increased cannabis use frequency. 
The study results are, again, most relevant to the maintenance phase of cannabis use. It is noteworthy that 
although discomfort and perceived distress intolerance were significantly negatively related, the size of 
association was modest (r = -.16, p < .02), and therefore, supports that while the two constructs are related, 
they are distinct (Buckner et al., 2007). Yet, this investigation did not sample expressly for cannabis users 
and did not ascertain whether distinct types of distress or discomfort intolerance were uniquely related to 
particular aspects of cannabis using behavior.  
In another investigation, Zvolensky et al. (2009) examined anxiety sensitivity, distress intolerance, 
and fear reactivity to bodily sensations (induced in a laboratory biologic challenge paradigm) in one 
overarching model in relation to coping and conformity cannabis use motives among a sample of young 
adult cannabis users (n = 135; 46.7% women; Mage = 20.45, SD = 5.0). In terms of ethnic background, 95% 
of participants identified as Caucasian, 0.7% African-American,0.7% Asian, .7% Hispanic, 0.7% bi- or 
multiracial, 1.5% other, and 0.7% did not provide ethnic data. Sixty-seven percent of the sample smoked 
cannabis at least once per week and 24.4% smoked more than once per day. The mean age for first time 
cannabis use was 14.96 (SD = 2.2) years, and the mean age of onset for regular cannabis use was 15.4 (SD 
= 4.89) years. After controlling for current cannabis use frequency (past 30 days), daily cigarette smoking 
rate, average volume of alcohol used over the past year, negative affectivity, and other cannabis use 
motives, anxiety sensitivity was significantly and uniquely associated with coping and conformity motives 
for cannabis use. Perceived distress intolerance, measured by the DTS, evidenced significant and unique 
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incremental relations only to coping motives whereas fear reactivity to bodily sensations was unrelated to 
any cannabis use motive. These results suggest that perceived distress intolerance, as measured by the DTS, 
is uniquely concurrently related to coping-oriented cannabis use. As in other work, the study results are 
perhaps most relevant to the maintenance phase of cannabis use. It is unclear, however, if such results are 
applicable to: (1) desire to quit, (2) perceived ability to quit, (3) severity of withdrawal symptoms, and (4) 
severity of cannabis use problems.  
Potter, Vujanovic, Marshall-Berenz, Bernstein, and Bonn-Miller (2011) examined the explanatory 
role of perceived distress intolerance in the context of posttraumatic stress symptoms severity and cannabis 
use coping motives in a sample of adults (n =142; 46.5% women; Mage = 22.18, SD = 7.22; 95.8% 
Caucasian, 0.7% Asian, 0.7% Hispanic/Latino, and 1.4% “other”) who endorsed exposure to a traumatic 
event (Criterion A; DSM-IV-TR, 2000) and reported use of cannabis in the past 30 days. Results indicated 
that (1) higher levels of posttraumatic stress symptom severity was  significantly associated with greater 
levels of cannabis use coping motives; (2)  posttraumatic stress symptom severity demonstrated a positive 
association with perceived distress intolerance; and (3) the association between posttraumatic stress 
symptom severity and cannabis use coping motives diminishes when perceived distress intolerance is 
entered into the model (Potter et al., 2011). These findings suggest that perceived intolerance of emotional 
distress could be an important mechanism underlying the association between posttraumatic stress and 
cannabis use coping motives (e.g., to manage emotional distress; Potter et al., 2011). The cross-sectional 
test of is one important limitation to the investigation. Additionally, this study did not focus on a severe 
cannabis-using population. 
Bujarski, Norberg, and Copeland (2012) more recently examined the mediating role of coping 
motives in cannabis use-related problems and perceived distress intolerance. The sample included 118 
participants collected from an Australian community sample (33.9% female; Mage = 29.84, SD = 12.41), 
who reported at least monthly use of cannabis. Participants completed a battery of self-report measures 
prior to arriving for their research visit; thereafter, the Structured Clinical Interview for the DSM-IV 
(SCID-IV) and Time Line follow Back (TLFB) were administered (Bujarski et al, 2012). Criteria for 
current (e.g., within the past month) cannabis use was met by 5.9% of the sample, while 66.9% met criteria 
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for cannabis dependence, with 12.7% of the sample meeting criteria for alcohol abuse and 21.2% for 
alcohol dependence (Bujarski et al., 2012). Results of the study indicated that (1) individuals who met 
criteria for a CUD were significantly less tolerant of distress compared to those without a CUD; (2) 
quantity of cannabis use was not related to perceived distress intolerance; and (3) females were less tolerant 
of distress than males. This study did not address the role of perceived distress intolerance in terms of 
perceptions of quitting, self-efficacy for abstaining, or consider the role of behavioral indices of distress 
intolerance.  
In the most recent study, Dvorak and colleagues (2014) examined predictors of cannabis use and 
cannabis-related problems among college students recruited via email.  Findings indicated a relation 
between perceived distress intolerance and the liklihood of experiencing a higher level of cannabis-related 
problems (Dvorak & Day 2014). Moreover, when behavioral and emotional indices of "emotional 
instability” (indexed by scales of impulsivity/self-control and sensation seeking) were modeled 
simultaneously, perceived distress intolerance emerged as the variable that was more strongly related to 
cannabis use problems.  
2.2.1. Summary of Key Limitations 
Existing work on distress intolerance and cannabis use and its disorders has been productive, but it 
also is narrow in scope. Indeed, there are only a limited number of existing studies completed to date. 
Consequently, there are a number of key limitations of this line of research. First, existing work has not 
addressed the role of distress intolerance in regard to indices of quit success or failure. Thus, it is unclear if, 
and to what extent, perceived  or behavioral distress intolerance is directly related to cannabis quit 
behavior.  
Second, some initial work has begun to address the role of distress intolerance in regard to severity 
of cannabis use problems, but not yet in relation to self-efficacy for maintaining abstinence, or perceptions 
of barriers to quitting. Thus, it is unclear if distress intolerance, in general, is related to these other highly 




Third, none of the past work has sought to examine perceived and behavioral indices of distress 
intolerance in terms of cannabis use behavior in one overarching model. Given evidence that suggests that 
distress intolerance may have distinct latent structure (Bernstein et al., 2011), it is possible perceived and 
behavioral aspects of distress intolerance may be differentially related to certain aspects of cannabis use, or 
even synergistically confer greater risk for certain cannabis-using problems (i.e., their combination may be 
more apt to be related to cannabis use problems than their singular effects). 
Finally, past work has sampled predominately Caucasian samples with relatively high degrees of 
education. Yet, individuals below the poverty line and from racial and ethnic minority groups are at 
heightened risk for CUD and difficulty in quitting (Copersino et al., 2010; Johnston et al.,, 2013; NIDA, 
2012; SAMHSA, 2014) and may endorse different motives for cannabis use (e.g., coping, social, and 
conformity motives are related to greater cannabis use impairment among African Americans but not 
Whites; Buckner, Shah, Dean, & Zvolensky, in press). Notably, the 'sampling' of  cannabis using 
participants in previous work has been focused largely Caucasian users from middle socioeconoic strata. 
Moreover, past studies have not sampled  exclusively for CUD, but rather, included a wider range of 
cannabis use as study inclusionary criteria. Therefore, it is important to evaluate the generalizability of past 
work to a CUD group with lower  socieconomic status  who also is comprised, in part, from 
underrepresented ethnic minority groups. Indeed, numerous studies suggest a major contributing factor to 
substance use among lower socieconomic and underrepresented groups appears be the increased exposure 
to multiple stressors associated with low socioeconomic environments (e.g., low social cohesion, high 
unemployment), which in turn, may contribute to disruptions in emotional processes, including emotion 
regulatory processes (Cuevas et al., 2014; Doan & Evans, 2011; Evans & Fuller-Rowell, 2013; Reitzel et 
al., 2013). These findings are possibly relevant to distress intolerance because a decreased capacity to 
withstand stress may be related to more severe substance use behavior. At the same time, because of the 
'rich stress levels' associated with lower socieconomic environments, it is remains unclear if distress 
intolerance will operate in the same fashion as that observed among other socieconomic levels.  
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CHAPTER 3: INTEGRATING DISTRESS INTOLERANCE IN CANNABIS USE  
3.1. A Working Theoretical Model 
Based on findings and related advances relevant to distress intolerance and CUD, I constructed a 
preliminary integrative synergistic type of model of CUD that is theoretically most applicable to the 
maintenance and relapse phases of cannabis use. At its core, this model recognizes that a quit attempt is a 
demanding life event that challenges the individual to draw from self-regulatory skills as well as socio-
environmental resources to attain and maintain abstinence.  
3.1.1. Perceived Distress Intolerance 
Based on extant biopsychosocial models and empirical evidence focused on distress intolerance, 
persons with elevated levels of perceived intolerance for negative emotional events may tend to be more 
emotionally reactive to stressors while quitting and coping with emotionally distressing events, thoughts, 
and feelings during active periods of cannabis use by trying to escape or avoid them (i.e., coping-oriented 
motives for cannabis use; Leyro et al., 2010). That is, the perceived expectation to not be able to effectively 
tolerate emotional distress may influence the type of cannabis use (e.g., using for coping-oriented motives 
predominately or instead of other more potentially healthy motives such as enhancement motives). To the 
extent an active cannabis user has higher levels of perceived distress intolerance, they may be more likely 
to expect or objectively experience more problems while quitting, maintain less confidence in their ability 
to maintain abstinence, and perhaps develop more severe use patterns. Ultimately, such perceived distress 
intolerance may make quitting more difficult because these individuals are already 'primed' for negative 
expectations about quitting before embarking in such an attempt, or be related to more severe problems of 
use, in part, because they may be using predominately for mood-dampening motives (coping-oriented use).   
3.1.2. Behavioral Distress Intolerance 
Behavioral distress intolerance also is likely to maintain explanatory value for the maintenance 
and relapse phases of cannabis use. Past work has shown behavioral indices of distress intolerance for 
cognitive stress are related to less persistence in a quit attempt among polysubstance using persons 
(Daughters et al., 2005). Additionally, higher levels of behavioral intolerance to acute episodes of ongoing 
aversive states are related to substance use relapse (Brown et al, 2002). Although there has not been a test 
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of behavioral distress intolerance and cannabis per se, it would be fruitful to examine the possibility that 
behavioral intolerance may relate to cannabis lapse and relapse, further contributing to maintenance of 
cannabis use. Such an observed relation may 'mimic' the experience that those with CUD may undergo 
while trying to abstain from cannabis, theoretically, relating to both the maintenance and relapse phases of 
cannabis use. For example, it may be that those who are experiencing more severe cannabis withdrawal 
symptoms or bodily stress re-initiate use of cannabis during their quit attempt in an effort to 'downregulate' 
aversive physical symptoms. Such patterns of use may strengthen a (presumably learned) relation between 
bodily stress and negative reinforcement-based cannabis use. Ultimately, greater behavioral distress 
intolerance may strengthen the negative reinforcement learning that occurs between bodily stress-coping-
oriented cannabis use, perhaps contributing to more problems while quitting, less confidence beliefs about 
maintaining abstinence, and more severe use patterns.  
3.1.3. Interplay (theoretical) between Perceived Distress Intolerance and Behavioral Distress 
Intolerance  
In addition to the potential individual roles of perceived and behavior distress intolerance, these 
two variables (perceived and behavioral distress intolerance) may interplay with one another in a clinically-
relevant manner. As noted earlier, existing data suggest that self-report and behavioral distress intolerance 
indices may possibly not reflect individual differences of a common latent distress intolerance variable 
(e.g., they are often not correlated strongly with one another; Bernstein et al., 2011), and therefore, may 
benefit from recognizing the distinction between self-report and behavioral tolerance constructs (Leyro et 
al., 2010). Indeed, persons with CUD with higher levels of perceived distress intolerance and higher 
behavioral distress intolerance for interoceptive distress (e.g., aversive physical sensations) may be more 
likely to manifest greater (a) problems in quitting; (b) severity of cannabis use problems; and (c) severity of 
problems experienced while quitting and self-efficacy for abstaining from cannabis use. That is, higher 
levels of intolerance for internal stress (e.g., bodily perturbation) may moderate the relation between 
perceived distress intolerance and numerous aspects of cannabis use problems. Specifically, persons with 
CUD expecting greater levels of emotion or physical dysregulation due to their beliefs about tolerating such 
distress (perceived distress intolerance), who also cannot as effectively tolerate such distress (behavioral 
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distress intolerance), may be more likely to interpret or objectively experience distressing symptoms as 
more severe. Conversely, higher levels of an ability to tolerate emotional or physical dysregulation may 
attenuate the relative risk for more CUD problems because they have a greater ability to tolerate aversive 
internal experiences that may trigger a return to coping-oriented use. 
3.1.4. Summary and Study Aims  
Overall, the primary aim of the present study was to examine the main and interactive effects of 
perceived and behavioral indices of distress intolerance in terms an array of clinically-relevant cannabis 
quit-related variables.  
First, it was hypothesized that among persons with current CUD, perceived (measured using 
Distress Tolerance Scale [DTS]; Simons & Gaher, 2005) and behavioral (measured using a voluntary 
breath-holding task; Asmundson & Stein, 1994) distress intolerance variables would interact to be 
significantly and uniquely associated (a) more failed quit attempts (lifetime quit failure index); and (b) 
shorter duration of average time to relapse for past quit attempts (measured in hours), reported for both the 
most recent quit attempt (within the past year), as well as longest period of abstinence ever achieved. The 
expected form of the interaction was posited to be that higher perceived and behavioral distress intolerance 
would be associated with greater failed quit attempts and shorter duration of time to relapse.  
Second, it was hypothesized that among active cannabis users with CUD, perceived (measured 
using DTS) and behavioral (measured using a voluntary breath-holding task) distress intolerance variables 
would interact to be significantly associated (a) greater severity of cannabis withdrawal symptoms 
experienced while quitting in the past; (b) lower self-efficacy for abstaining from cannabis use; and (c) 
greater perceived barriers for quitting. The expected form of the interaction was, again, such that higher  
perceived and behavioral distress intolerance will be associated with greater greater severity of quit 
problems, lower self-efficacy, and greater perceived barriers for quitting.  
Finally, it  was hypothesized that among active cannabis users with CUD, perceived (measured 
using DTS) and behavioral (measured using a voluntary breath-holding task) distress intolerance variables 
would interact to be uniquely associated with more severe cannabis use problems. The expected form of the 
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interaction was such that higher perceived and behavioral distress intolerance will be associated with 
greater CUD problems. 
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CHAPTER 4: METHOD  
4.1. Participants 
One-hundred fifty-five adults (29% female), who were actively using cannabis and met criteria for 
CUD, were recruited through newspaper and community flyer advertisements targeting individuals 
interested in participating in research related to their current cannabis use and past their past quit 











Figure 2: Consort of Participant Recruitment 
Of the 155 participants, 110 (71%) were male and 45 (29%) were female. The mean age of 
participants was 37.2 years (SD = 11.7 years). Twenty percent of participants identified their ethnicity as 
Hispanic or Latino. The majority of participants (61.9%) were Black or African American, with the 
remainder of the participants identifying as White (29%), Asian (2.6%), American Indian or Alaskan 
Native (0.6%). The remaining 5.8% of the sample did not provide data on their race or ethnicity. 
4.2. Inclusion/Exclusion Criteria 
Participants were (1) between 18 and 65 years of age, (2) met DSM-IV criteria for current CUD, 
(3) were active user of cannabis (operationally defined as smoking at least three days per week for a period 
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with one of the attempts occurring in the past year (i.e., an effort to help ensure participants with quit 
attempts were sampled). 
Participants were excluded from the study based on evidence of: (1) current suicidal or homicidal 
ideation, (2) current psychosis, (3) limited mental competency (not oriented to person, place, or time), (4) 
the inability to give informed, voluntary, written consent to participate, (5) current professional treatment 
for CUD or other substance use problems (i.e., participants were not excluded for past cannabis or 
substance use treatment), (6) recent legal mandate limiting cannabis use [e.g., incarceration during their 
‘quit attempt’], (7) use of cannabis explicitly for a medical disorder, or (8) pregnancy or current 
breastfeeding. See Table 2. 
4.3. Measures 
Demographics Questionnaire. Participants completed a demographics form, which was used to 
capture the age, race, ethnicity, sex, gender, sexual orientation, education level, economic status, current 
occupation, and marital status of participants.  
Medical Problems. Participants completed a brief medical history questionnaire that focused on 
medical conditions relevant to criteria for the study (example item: please indicate if you have ever been 
diagnosed with any of the following: asthma). Medical conditions that were listed on the scale included the 
following: epilepsy, stroke, head injury, heart problems (tachycardia, heart murmur), hypertension, 
diabetes, allergies, asthma, and respiratory disease. This medical checklist has been used successfully in 
past work among clinical and nonclinical populations as part of laboratory screening protocals (Farris, 
Zvolensky, Otto, & Leyro, in press; Zvolensky et al., 2004) and was used in the current dissertation to 
exclude research participants based on study criteria as well as to assess for some common medical 
problems. 
Structured Clinical Interview-Non-Patient Version for DSM-IV (SCID-IV-NP; First, Spitzer, 
Gibbon, & Williams, 1995). The SCID-IV-NP is a structured diagnostic interview that assesses Axis I 
psychopathology according to the DSM-IV-TR (First et al., 1995). Diagnostic exclusions and prevalence of 
current Axis I diagnoses (e.g., substance use disorders, mood disorders, and anxiety disorders) was 
determined using the SCID-IV-NP (First et al.,, 1995). In the current dissertation, the SCID-IV-TR was 
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used to determine the presence of CUD. Random reliability checks of 20% of cases were conducted to 
establish diagnostic agreement rates between interviewers. Reliability checks were conducted by trained 
and supervised post-bac research assistants or doctoral-level clinical psychology graduate students for 
diagnostic agreement. No cases of disagreement were observed.  
Distress Tolerance Scale (DTS; Simons & Gaher, 2005). The DTS (Simons and Gaher, 2005) is a 
14-item measure that assesses ones’ evaluation and expectation of experiencing negative emotion on a five-
point likert scale (1= Strongly Agree to 5= Strongly Disagree; example item: There’s nothing worse than 
feeling distressed or upset). The DTS, self-reported measurement of perceived distress intolerance, includes 
four subscales: (1) perceived ability to tolerate emotional distress (example item: Feeling distressed or 
upset is unbearable to me); (2) the degree level an individual's attention is absorbed by negative emotions 
(example item: My feelings of distress are so intense that they completely take over); (3) efforts to regulate 
affect in an effort to reduce distress (example item: I’ll do anything to stop feeling distressed or upset); and 
(4) subjective appraisal of distress (example item: I am ashamed of myself when I feel distressed or upset). 
The DTS yields good internal consistency with stable measurement over a 6-month period (alpha 
coefficient = .89; Simons and Gaher, 2005). Internal consistency for the total score of the DTS in the 
present study was excellent (α = .91), and was adequate for all four subscales (α ranges = .69-.79).  
 Breath-Holding Task (Asmundson & Stein, 1994). The breath-holding task (Asmundson & Stein, 
1994) is a behavioral assessment of distress intolerance. During the task, participants were read a 
standardized script instructing them on how to complete the task. In general, participants would inhale as 
deeply as possible and then exhale once a full breathe is achieved. At the completion of the exhalation, the 
participant, again, would breath in as deeply as possible and holds their breath as long as they can. The 
length of time the participant is able to hold their breath was collected via a digital stopwatch. The task was 
then repeated after a three minute rest period. For the purposes of this study, duration of the second 
breathholding trial was used as the behavioral index of distress intolerance; this second score provides a 
more reliable index than the first trial (correlation between time one and time two: r = .85). Importantly, 
recent research has suggested breath-holding duration maintains unique explanatory value relative to 
physical health problems, active substance use, and anxiety sensitivity in the prediction of other distress 
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intolerance processes, such as discomfort intolerance and mirror-tracing task persistence (Hogan, Farris, 
Brandt, Schmidt, & Zvolensky, 2014). In the current study, the observed range of breath holding time 
ranged from 1 to 96 seconds, with an average of 43 seconds (SD = 22 seconds). 
 Self-efficacy for Quitting (SEQ; Marlatt & Gordon, 1985). The SEQ is a 19-item measure based 
on the Marlatt and Gordon (1985) categories of relapse situations (e.g., being with others who are using) 
which measures the degree to which one feels confident in their ability to not use marijuana across different 
‘high risk’ situations on a likert-type scale (1 = not at all confident  to 7 = extremely confident). The SEQ 
measures a single dimension of self-efficacy for quitting and has high internal consistency (alpha 
coefficients ranging from .89-.94 when used for pre-treatment and post-treatment, respectively). Internal 
consistency for the SEQ in the present study was excellent (α = .90). 
Marijuana Problems Scale (MPS; Stephens, Roffman, & Curtin, 2000). The MPS is a 
psychometrically sound 19-item list of negative social, occupational, physical, and personal consequences 
associated with marijuana use in the past 90 days (Stephens et al., 2000). Respondents are asked to the rate 
the level of problems associated with their cannabis use on a likert-type scale (0 = no problem to 2 = 
serious problem) in response to problems such as, “problems between you and your partner,” or “legal 
problems.” Internal consistency for the MPS in the present study was good (α = .89). 
Marijuana Withdrawal Checklist (MWC; Budney, Novy, & Hughes, 1999). The MWC is a 22-
item self-report questionnaire that assesses the presence of marijuana withdrawal symptoms (example item: 
“decreased appetite,” “irritability”) on a four-point likert-type scale (0 = Not al all to 4 = Severe) during  
respondents most recent quit attempt. In the current study, the internal consistency for the MWC was 
excellent (α = .93). 
Barriers of Cannabis Cessation Scale (BCCS). The BCCS is conceptually informed by the Barriers 
of Cessation Scale (BCS; Macnee & Talsma, 1995), a 19-item measure that captures a respondent’s 
perceived barriers to cigarette smoking cessation (Macnee & Talsma, 1995). Items on the BCS were 
adapted to fit perceived barriers specific to cannabis cessation (example item: “being addicted to 
marijuana”), while some wording from the original measure was retained (example item: “fear of failing 
to quit successfully”). In total, 18 items from the original measure were adapted for participants to respond 
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to barriers of cessation for cannabis by our research team with permission from the authors of the original 
scale. Consistent with the original questionnaire, respondents were asked to report the level of agreement 
they had with each statement (e.g., 0 = not a barrier/not applicable to 3 = large barrier). Internal 
consistency for the BCCS in the present study was excellent (α = .91). 
Marijuana Smoking History Questionnaire (MSHQ; Bonn-Miller & Zvolensky, 2009). The 
MSHQ is a self-report instrument that measures respondents’ cannabis use history with questions 
pertaining to cannabis smoking rate, age of onset at initiation, years of being a ‘regular’ cannabis smoker, 
and other descriptive information (e.g., number of past quit attempts). The MSHQ was used at the 
appointment to assess cannabis smoking use history, patterns of use, and interest in and nature of quit 
experiences.    
Positive and Negative Affect Scale (PANAS; Watson, Clark, & Tellegen, 1988). Negative 
affectivity was assessed using the 20-item Positive and Negative Affect Schedule (PANAS), which asks 
research participants to indicate on a likert-type scale (1 = very slightly or not at all to 5= extremely) how 
they generally feel according to a list of various feelings and emotions (example items: Interested, Nervous, 
Ashamed; Watson et al., 1988). The scale measures two factors, negative and positive affect, with both 
scales demonstrating high levels of internal consistency (alpha coefficients for the positive and negative 
affect scales are .86 and .87, respectively; Watson et al., 1988). Internal consistency for the PANAS in the 
present study was excellent (α = .96).  
Alcohol Use Disorders Identification Test (AUDIT; Babor, de la Fuente, Saunders, & Marcus, 
1992). The AUDIT is a 10-item self-report screening measure developed for the World Health 
Organization to identify individuals whose alcohol use is hazardous (Babor, de la Fuente, Saunders, & 
Grant, 1992). There is a large body of literature attesting to the psychometric properties of the AUDIT 
(e.g., Saunders, Aasland, Babor, de la Fuente, & Grant, 1993). The AUDIT total score was utilized to 
characterize problematic alcohol use within the current sample and recommended employed gender-
specific cut-points (Saunders et al., 1993). Within the current sample, internal consistency was excellent (α 
= .90).  
 30 
 
Fagerstrom Test for Nicotine Dependence (FTND; Heatherton, Kozlowski, Frecker, & 
Fagerstrom, 1991). The FTND is a six-item scale that assess tobacco dependence. In the current study, the 
FTND total score was used to characterize participant levels of tobacco dependence. The FTND has been 
generally found to have high test-retest reliability (Heatherton et al., 1991), but internal consistency that is 
only adequate (α = .60).  
4.4. Procedure 
Participants who responded to the study advertisements were first screened by telephone in order 
to determine whether or not the potential participant met the initial inclusion or exclusion criteria (see 
Table 2). Thereafter, participants who were 'potentially eligible' were scheduled for an in-person baseline 
assessment. Participants were asked to not use cannabis prior to the assessment. In addition, participants 
were asked to provide the time of their last use of cannabis. During the baseline appointment, participants 
provided written informed consent, and then, were interviewed using the SCID-NP to establish inclusion 
criteria of CUD. Those who met inclusion criteria continued on to the baseline assessment, which consisted 
of self-report questionnaires and distress intolerance tasks (see Table 3). At the completion of the 
assessment, participants were compensated with a $20.00 gift card for their time (approximately 3 hours). 
All participants provided written informed consent prior to initiating study procedures. The study protocol 
was approved by Institutional Review Board at the University of Houston. All procedures followed were in 
accordance with the ethical standards of the responsible committee on human experimentation (institutional 
and national) and with the Helsinki Declaration of 1975. 
4.5. Analytic Strategy 
Data analysis was completed with SPSS Statistics 22. Data that were not entered directly by 
participants via an internet-based survey (www.Qualtrics.com) was double entered by (independent) 
researcher assistants in two separate databases and compared for consistency. Data that were entered 
directly by participants were downloaded directly from the data service. All data points were first screened 
for outliers by examining descriptive data, and verifying that observed values fell within the expected range 
of scores for each variable. Any data point identified as an outlier, which could not be resolved by 
examining the raw data, was deleted. Thereafter, data was screened for normality by examining histograms, 
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plots, and values of skewness and kurtosis. Several of the variables of interest demonstrated either 
skewness or kurtosis (i.e., longest quit duration, most recent quit duration, and cannabis use problems 
(Stephens et al., 2000); therefore, LOG10 transformations were performed. 
First, descriptive data on the study variables were explored in terms of frequency of endorsement. 
Second, a series of bi-variate correlations was conducted to examine associations between study variables. 
Then, to test the main and interactive effects of perceived distress intolerance (DTS total score) and 
behavioral distress intolerance (breath holding duration) on the criterion variables, a moderation analysis 
using PROCESS macro (Hayes & Preacher, 2013) was conducted. In the first step of each model, 
covariates were entered that were found to maintain a significant bivariate correlation with the designated 
dependent variables. Next, perceived distress intolerance and behavioral distress intolerance were 
simultaneously entered in the second step. Finally, the interaction term between perceived distress 
intolerance and behavioral distress intolerance was entered at the third step. In the case of missing data, 
listwise deletion was applied, resulting in sample sizes ranging from 148 to 155 across analyses. 
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CHAPTER 5: RESULTS  
5.1. Descriptive Data 
5.1.1. Living Situation, Educational Background, and Financial Status 
 The current sample largely self-identified as living in an urban area (64.5%) with the remaining 
sample identifying as either living in sub-urban (23.9%) or rural areas (10.3%). The majority of the sample 
identified their relationship status as single (68.4%), followed by married (8.4%), divorced (7.1%), 
widowed (3.2%), or separated (2.6%). Only 14.8% of the sample completed college, with 5.8% attending 
graduate school. Of those remaining, 46.5% completed part of college, 26.1% completed high school or 
equivalent, and 5.2% completed less than 8 years of education. Participants reported on their highest 
occupations level: executive (0.6%), manager/professional (24.5%), administrative (6.5%), clerical (7.7%), 
skilled (32.9%), semi-skilled (19.4%), unskilled (6.4%), and never worked (1.9%).  
 Employment status was as follows: full-time employment (18%), part-time employment (31%), 
dependent on spouse/student (9%), recipient of public assistance (13%); 29% of the sample did not find this 
question “applicable.” In the past three years, 16% of the sample was employed “virtually all of the time,” 
34% was employed “most of the time,” 27% was employed “half of the time” to “less than half of the 
time,” and 23% was employed “briefly” or “not at all,” with 40% of the sample having “no limitations for 
employment,” 18% “attending school,” and the remainder of the sample identifying house responsibilities, 
job market, retirement, physical illness, psychopathology, or institutionalization as reasons limiting 
employment (42%).  
 In regard to income level, 16.8% of the sampled chose not to provide data related to their finances. 
The remaining sample fell within the following income ranges: $0 to $4,999 (17.4%), $5,000 to $9,999 
(10.3%), $10,000 to $14,999 (18.1%), $15,000 to $24,999 (11.6%), $25,000 to $34,999 (13.5%), $35,000 
to $49,999 (10.3%), $50,000 to $74,999 (0.6%), and greater than $75,000 (1.3%).  Therefore, 
approximately 70% of the sample (conservatively estimated) earned less than $35,000 per year, a value 
consistent with most poverty categorizations in the US (Evans & Fuller-Rowell, 2013; Kendzor et al., 




5.1.2. Cannabis use 
 On average, participants smoked on 6 days per week, with a mean of 26 episodes of cannabis use 
per week (range: 2 - 77, SD = 26.2), and the average years of cannabis use was 14.2 (SD = 11.2 years). 
Average age of first use was 15.6 years old (range: 6-33, SD = 3.9 years), with an average age of 19.7 
indicated as the age when regular cannabis use was initiated (range: 3-47, SD = 5.5 years). Overall, the 
majority of participants indicated they most commonly consumed cannabis in the form of a joint (52.9%) or 
blunt (24.5%), others reported most common use via a “bowl” (12.3%), bong (7.7%), “one-hitter” (1.3%), 
or vaporizer (0.6%); one participant did not complete the question, and none of the participants indicated 
ingestion as their primary method of cannabis consumption. About half of participants indicated they 
typically smoke cannabis alone (49.7%), the other half stated a preference of smoking with two to three 
people (47.7%), and only 2.6% reported smoking cannabis with a group of more than three people. On 
average, participants reporting using 3.8 times per week (range: 0-20, SD = 3.05), with 30% of the sample 
indicating they smoked cannabis more than once per week, and 61% of sample indicting they smoked 
cannabis more than once per day. The remaining 9% of sample indicated they were using cannabis once per 
week or less; in these instances, reasons for 'non-use' were reported to be financially-driven (i.e., the person 
lacked the financial resources to purchase cannabis). 
5.1.3. Tobacco and Alcohol Use 
 In terms of tobacco use, 59.2% of the sample identified as a current cigarette smoker, with an 
average level of nicotine dependence of 3.36 (SD = 1.71), indicating low to moderate levels of nicotine 
dependence (Heatherton et al., 1991). The average AUDIT score for the sample was 8.99 (SD = 8.4), 
indicating, on average, harmful levels of alcohol use (Saunders et al., 2006). Of the 79% of participants that 
endorsed harmful patterns of alcohol use based upon AUDIT criteria, 59% were a current smoker 
(tobacco). 
5.1.4. Psychiatric History 
 In terms of psychopathology, participants were assessed for the presence of current (past year) 
anxiety, substance use, and mood diagnoses. The most common clinical conditions were anxiety disorders, 
with 36.1% of the sample meeting criteria for an anxiety disorder (n = 56), 19% meeting criteria for an 
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anxiety and mood disorder, and 9% meeting criteria for an anxiety disorder and an additional substance use 
disorder (see Table 4). Of those with an anxiety or related type of disorder (dissociative psychopathology), 
the most common condition was posttraumatic stress disorder (PTSD; 21.3%), followed by a specific 
phobia (5.2%), generalized anxiety disorder (3.2%), social anxiety disorder (2.6%), panic disorder (1.9%), 
anxiety disorder not otherwise specified (1.3%), and obsessive-compulsive disorder (0.6%). In terms of 
mood disorders, 26.4% met criteria for a mood disorder, 12.3% of the sample met criteria for a co-
occurring mood and anxiety disorder, and 5.8% met criteria for a mood disorder and a substance use 
disorder. Of those with a mood disorder, the most common condition was major depressive disorder 
(16.1%), followed by dysthymia (5.8%), bipolar I (2.6%), and bipolar II (1.9%).  Only a minority of 
participants met criteria for a substance use disorder (5.8%), but no other Axis I disorder, and none met 
criteria for poly substance abuse or dependence, operationalized per the DSM-IV-TR criteria. Overall, 25% 
of the sample met criteria for more than one Axis-I disorder in the past year. 
5.1.5. Physical Health  
 In terms of physical health problems, 56.1% of current sample identified one or more current 
physical health disorders via the brief checklist, including respiratory problems, diabetes, heart condition, 
hypertension, epilepsy, or head trauma. Interestingly, 18.1% of the sample indicated they currently have 
physical symptoms that they believed are caused by smoking cannabis, 2.6% of the sample indicated they 
believe smoking cannabis aggravates a current disease or illness, and 30.6% of participants endorsed 
receiving 'relief from cannabis' for physical symptoms, or a disease or illness (see Table 4). 
5.2. Bi-Variate Correlations 
Table 5 lists the bivariate correlations among the study variables. First, as expected, perceived 
distress intolerance was significantly negatively related to cannabis withdrawal (r = -.21, p < .01), 
perceived barriers to cannabis cessation (r = -.24, p < .01), and severity of cannabis use problems (r = -.17, 
p < .05). The relation of perceived distress intolerance with cannabis withdrawal, perceived barriers to 
cannabis cessation, and severity of cannabis use problems were small to moderate using conventional 
benchmarking indices (Cohen, 1988). In contrast to prediction, perceived distress intolerance was not 
significantly related to total lifetime quit attempts (r = .09), longest abstinence duration ever achieved (r = -
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.05), or abstinence duration during the most recent quit attempt (r = .12). Perceived distress intolerance was 
positively, but not significantly, related to total lifetime quit attempts (r = .09) and recent abstinence 
duration (r = .15).  
Second, in regard to behavioral distress intolerance, in contrast to expectation, no significant 
relations were observed with the criterion variables (r's range: -.11 to -.03).  
Third, as expected, there was no significant association between the perceived distress intolerance 
and behavioral distress intolerance variables.  
Fourth, also as expected, a significant negative association between perceived distress intolerance 
and negative affect was observed (r = -.34, p < .01). Yet, behavioral distress intolerance and negative affect 
were not correlated. 
Finally, several significant associations were observed between the possible covariates and 
dependent variables. First, respiratory conditions were related to cannabis withdrawal (r = .18, p < .05). 
Second, negative affectivity was significantly associated with cannabis withdrawal (r = .34, p < .01), self-
efficacy for quitting cannabis use (r = .20, p < .05), perceived barriers to cannabis cessation (r = .32, p < 
.01), and severity of cannabis use problems (r = .33, p < .01); these relations were generally moderate to 
large (Cohen, 1988). Gender also was significantly negatively associated with cannabis withdrawal (r = -
.22, p < .01) and perceived barriers to cannabis cessation (r = -.16, p < .01), such that women were more 
likely than men to indicate higher levels of cannabis withdrawal and report greater  barriers to cannabis 
cessation. 
5.3. Regression Models 
Aim 1. No covariates were identified in this model based upon bi-variate relations for lifetime quit 
attempts. In the first step, perceived distress intolerance and behavioral distress intolerance were entered, 
but they were not significant predictors of lifetime quit attempts (R2 = .02, F(3, 149) = .97, p = .41). The 
interaction term also was not significant (see Table 6). 
For  longest abstinence duration achieved, again, no covariates were employed due to the lack of 
significant bi-variate relations. Also, perceived distress intolerance and behavioral distress intolerance were 
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not significant predictors of abstinence duration (R2 = .02, F(3, 149) = .82, p = .48). The interaction term 
was not significant (see Table 6). 
For duration of abstinence during most recent quit attempt (see Table 6), no significant effects 
were evident for the main or interactive effects of perceived distress intolerance and behavioral distress 
intolerance (see Table 6).   
Aim 2. At the first step in the model, negative affectivity  accounted for a significant amount of 
variance in relation to cannabis withdrawal (β = .62, p < .001), whereas gender approached, but did not 
reach, traditional statistical significance (β = -5.81, p = .06). In step two, no significant effects were evident 
for perceived distress intolerance or behavioral distress intolerance. The interaction term was not 
significant (see Table 7). 
For self-efficacy for quitting, negative affectivity accounted for a significant amount of variance at 
step one in the model (β = .45, p < .05). No other significant effects were observed (see Table 7). 
 In terms of perceived barriers to cannabis cessation, negative affectivity was a significant 
predictor at step one (β = .45, p < .01; see table 7). No other significant effects were observed (see Table 8). 
Aim 3. Regarding cannabis use problems, negative affectivity, entered as the only covariate in step 
one, was a significant predictor (β = .01, p < .001). Distress intolerance, breath holding duration, or the 
interaction term were not significant predictors (see Table 8). 
5.4. Post Hoc Tests 
5.4.1. Perceived Distress Intolerance Subscales 
Due to the lack of significant effects for the hypotheses as well as the lack of significant effects in 
general, I sought to further explore the data with a select number of theoretically-driven post hoc analyses. 
The first examination focused on the bi-variate relations between perceived distress intolerance subscales 
and the dependent variables (see Table 9). The underlying logic being that it is possible that at least for 
perceived distress intolerance, specific subfactors may maintain stronger relations to the dependent 
variables than the total score (i.e., specific facets of distress tolerance may showcase stronger [or weaker] 
relations to particular cannabis use variables). To further explore these relations, all subscales from the 
distress intolerance scale (DTS; Simons & Gaher, 2005), used as the measurement of perceived distress 
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intolerance, were included. As described earlier in the Method Section, the DTS includes four subscales: 
(1) perceived ability to tolerate emotional distress (example item: Feeling distressed or upset is unbearable 
to me); (2) the degree level an individual's attention is absorbed by negative emotions (example item: My 
feelings of distress are so intense that they completely take over); (3) efforts to regulate affect in an effort 
to reduce distress (example item: I’ll do anything to stop feeling distressed or upset); and (4) subjective 
appraisal of distress (example item: I am ashamed of myself when I feel distressed or upset). 
The absorption subscale was significantly negatively related to cannabis withdrawal (r = -.25, p < 
.01), perceived barriers to cannabis cessation (r = -.26, p < .01), and cannabis use problems (r = -.21, p < 
.05). Second, the perceived distress intolerance appraisal subscale was significantly negatively related to 
cannabis withdrawal (r = -.23, p < .01) and perceived barriers to cannabis cessation (r = -.24, p < .01). 
Third, the perceived distress intolerance regulation subscale was negatively related to cannabis withdrawal 
(r = -.21, p < .05) and perceived barriers to cannabis cessation (r = -.20, p < .05). Fourth, the perceived 
distress intolerance tolerance subscale was significantly negatively related to cannabis withdrawal (r = -.17, 
p < .05) and perceived barriers to cannabis cessation (r = -.21, p < .05). None of the four perceived distress 
intolerance subscales were associated with lifetime quit index, longest abstinence duration, or abstinence 
duration during most recent quit attempt. Notably, the perceived distress intolerance subscales, as would be 
expected, were significantly interrelated to one another (range of r's: .57-.89; range of shared variance: 
32%-79%). 
Because significant perceived distress intolerance subscale effects were observed, I next sought to 
explore whether the perceived distress intolerance facets (subscales) were related to the dependent 
variables. Accordingly, wherein significant bi-variate relations were observed, a regression model was 
conducted with negative affectivity entered as a covariate at the first step and the perceived distress 
intolerance subscales (rather than the total score) entered at the second step (simultaneous entry). 
Therefore, the dependent measures for these analyses were: cannabis withdrawal, perceived barriers to 
cannabis cessation, and severity of cannabis use problems. 
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For cannabis withdrawal, negative affectivity was the only significant predictor (β = .34, p < 
.001). None of the perceived distress intolerance subscales evidenced significant incremental relations with 
cannabis withdrawal (Table 10). 
For cannabis use problems, again, only negative affectivity was significant predictor (β = .34, p < 
.001; see Table 10).  
For perceived barriers to cannabis cessation, negative affectivity was the only significant predictor 
(β = .32, p < .001; Table 10).  
5.4.2. Explanatory Role of Negative Mood 
A second set of theoretically-driven post hoc tests were then completed given the most consistent 
relation observed across analyses was between negative mood and a select number of the cannabis 
dependent variables. Specifically, the potential explanatory role of negative affect in the association 
between perceived distress intolerance and cannabis dependent variables was completed. I focused on 
negative affect and perceived distress intolerance because these two variables showcased the strongest 
relations at the bi-variate level with a select number of the cannabis dependent measures and there was no 
robust evidence of a direct effect for distress intolerance in relation to the dependent variables (as noted in 
the primary results of the primary aims and first set of post hoc tests).  
Bootstrapping via the Indirect Macro (Preacher & Hayes, 2008), a computational tool for observed 
variable mediation analysis, was employed. As a non-parametric method, bootstrapping estimates the 
sampling distribution of an estimator based on resampling with replacement. The indirect effect was 
computed for the sample, resulting in an empirically generated sampling distribution (Shrout & Bolger, 
2002). Four models were tested for the cannabis variables of cannabis withdrawal (Y1), self-efficacy for 
quitting (Y2), barriers to cannabis cessation (Y3), and severity of cannabis use problems (Y4) employed as 
criterion variables. Perceived distress intolerance (total score on the DTS) was selected as the predictor 
variable and negative affect as the proposed explanatory variable. Ten thousand bootstrap re-samplings 
were conducted to detect the indirect effect of the proposed predictor on the outcome variable through the 
proposed mediator (i.e., the product of the beta coefficients of path a and path b; see Figure 3). A bootstrap-
 39 
 
confidence interval that does not include zero provides evidence of a significant indirect effect (Preacher & 
Hayes, 2008).  
Regression results for paths a, b, c, and c’ are presented in Table 11, which correspond to each of 
the four post hoc models.  
The total effect model with cannabis withdrawal was significant (R2y1,x = .12, df = 1, 150, F = 
19.90, p < .001; path c), as was the full model with the explanatory variable  (R2M,x = .13, df = 2, 149, F = 
10.94, p < .001). The direct effect (path c’) of perceived distress intolerance in terms of cannabis 
withdrawal after controlling for the explanatory variable was non-significant. Regarding the test of the 
indirect effect, higher levels of perceived distress intolerance (e.g., less ability to tolerate distress) was 
predictive of greater levels of cannabis withdrawal symptoms, indirectly, through higher levels of negative 
affect (effect a*b).  
For self-efficacy for quitting cannabis, the total effect model for SEQ (R2y2,x = .12, df = 1, 152, F = 
20.32, p < .001) and the full model with the  explanatory variable accounted for significant variance (R2M,x 
= .05, df = 2, 151, F = 4.19, p < .05). The direct effect of perceived distress intolerance on self-efficacy for 
quitting, after controlling for the explanatory variable, was non-significant. Higher scores of perceived 
distress intolerance were predictive of lower self-efficacy through greater negative affect. 
Regarding perceived barriers for quitting cannabis, the total effects model accounted for 
significant variance (R2y3,x = .11, df = 1, 148, F = 18.04, p < .001). The direct effect of perceived distress 
intolerance on barriers to cannabis cessation only approached significance after controlling for the 
explanatory variable. The indirect effect was estimated and revealed that perceived distress intolerance was 
predictive of greater perceived barriers to cannabis cessation indirectly through greater levels of negative 
affect. 
In regard to severity of cannabis use problems, results indicated that the total effects model 
predicted significant variance in severity problems (R2y4,x = .12, df = 1, 151, F = 20.18, p < .001). The full 
model with the explanatory variable predicted significant variance in severity of cannabis use (R2M, x = .12, 
df = 2, 150, F = 9.93, p < .001). The direct effect of perceived distress intolerance for cannabis use severity, 
controlling for the explanatory variable, was non-significant. The indirect effect was estimated and 
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indicated that higher levels of perceived distress intolerance was predictive of greater self-reported severity 
of cannabis use indirectly through greater levels of negative affect. 
Finally, each of the four 'explanatory variable' models was compared to alternative models as a 
method of further strengthening interpretation. In the first alternative model, the proposed outcome and 
explanatory variable were reversed; in the second model, the predictor and explanatory variable were 
reversed. Comparing alternative models with alternative variable sequences is recommended as an 
additional test of the hypothesized order of influence among the study variables in the absence of a 
prospective study design (Preacher & Hayes, 2008; Shrout & Bolger, 2002). Tests of the indirect effects in 
these reversed explanatory variable models were, again, estimated based on 10,000 bootstrap re-samples.  
In terms of cannabis withdrawal, an alternative model wherein perceived distress intolerance was 
the indirect predictor and negative affect as the direct predictor  variable was evaluated. The total (B = .74, 
SE = .16, 95% CI [.41, 1.06]) and direct effect (B = .66, SE = .17, 95% CI [.31, 1.01]) of negative affect for 
cannabis withdrawal were statistically significant with a non-significant indirect effect of perceived distress 
intolerance (B = -.14, SE = .11, Bootstrapped 95% CI [-.35, .07]). In the second alternative model, 
perceived distress intolerance was the direct predictor and cannabis withdrawal was the explanatory 
variable in the prediction of negative affect. The total (B = -.21, SE = .05, 95% CI [-.30, -.12]), direct (B = -
.17, SE = .05, 95% CI -.26, -.08]) and indirect effect of perceived distress intolerance (B = -.04, SE = .02, 
Bootstrapped 95% CI [-.08, -.01]) for negative affect were statistically significant. Importantly, the 
confidence interval for the indirect effect (a*b) did not include zero; therefore, there was empirical 
evidence for a putative bi-directional relation between negative affect and cannabis withdrawal (although as 
measured, these two constructs may tap a highly simlar construct with a 'common negative affect core').   
For self-efficacy for quitting, the total (B = .44, SE = .17, 95% CI [.90, .77]) and direct effect (B = 
.52, SE = .18, 95% CI [.16, .88]) of negative affect for self-efficacy for quitting were statistically significant 
with a non-significant indirect effect of perceived distress intolerance (B = .15, SE = .18, Bootstrapped 95% 
CI [-.07, .37]). In the second alternative model, wherein perceived distress intolerance was the direct 
predictor, the total (B = -.21, SE = .05, 95% CI [-.30, -.12]), direct effect (B = -.21, SE = .06, 95% CI [-.30, 
-.12]) and indirect effect (B = .00, SE = .01, Bootstrapped 95% CI [-.02, .03]) of perceived distress 
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intolerance on negative affect were statistically significant. Importantly, the confidence interval for the 
indirect effect (a*b), included zero. The alternative mediation model was not significant. Consequently, 
there was empirical support for negative affect explaining  the relation between perceived distress 
intolerance and self-efficacy for quitting. 
 In terms of barriers to cannabis cessation, the total (B = .51, SE = .13, 95% CI [.26, .77]) and 
direct effect (B = .43, SE = .13, 95% CI [.16, .69]) of negative affect on perceived barriers to cannabis 
cessation were statistically significant with a non-significant indirect effect of perceived distress intolerance 
(B = -.15, SE = .08, Bootstrapped 95% CI [-.31, .01]). In the second alternative model, the total effect of 
perceived distress intolerance (B = -.20, SE = .05, Bootstrapped 95% CI [-.29, -.11]), which was identified 
as the direct predictor, and the direct effects (B = -.16, SE = .05, Bootstrapped 95% CI [-.26, -.07]), with 
barriers to cannabis cessation identified as the indirect predictor, yielded significant paths in the prediction 
of negative affect.  The indirect path was also significant (B = -.04, SE = .02, Bootstrapped 95% CI [-.08, -
.01]), and the confidence interval for this path excluded zero, supporting a possible bi-directional relation 
between negative affect and perceived barriers to cannabis cessation. 
Finally, for severity of cannabis use problems, a similar pattern of findings emerged: both the total 
(B = .00, SE = .00, 95% CI .00, .01]) and direct effect (B = .00, SE = .00, 95% CI [.00, .01) of negative 
affect in relation to perceived barriers to cannabis cessation were statistically significant, but the indirect 
effect of perceived distress intolerance was non-significant (B = .00, SE = .001, Bootstrapped 95% CI [.00, 
.00]). However, in the second alternative model, with perceived distress intolerance identified as the direct 
predictor, the total effect (B = -.21, SE = .05, Bootstrapped 95% CI [-.30, -.12]),direct effect (B = -.18, SE = 
.04, Bootstrapped 95% CI [-.27, -.09]), and indirect effect (B = -.03, SE = .12, Bootstrapped 95% CI [-.07, -
.01]) in the prediction of negative affect, were significantly explained by severity of cannabis problems. 
The confidence interval for the indirect path excluded zero. 
5.4.3. Conceptually-Related Transdiagnostic‘Tolerance’ Variables 
Given the nascent developmental stage of research on distress intolerance in relation to cannabis 
use behavior, a final set of exploratory bi-correlations were computed that focused on the bi-variate relation 
between related variables and the designated cannabis dependent variables as well as negative affect. I also 
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computed zero-order relations between the perceived and behavioral distress intolerance variables and 
these conceptually-related tolerance variables. The additional transdiagnostic 'tolerance-related variables' 
included specifically fear of detox (Detox Fear Survey Schedule-27 [DFSS-27; Gentile & Milby, 1992]), 
experiential avoidance (Multidemensional Experiential Avoidance Questionnaire [MEAQ; Gamez et al. 
2011]), anxiety sensitivity (Anxiety Sensitivity Index-III [ASI-3; Taylor et al., 2007]), discomfort 
intolerance (Discomfort Intolerance Scale [DIS; Schmidt et al., 2006]), and emotion dysregulation 
(Difficulties in Emotion Regulation Scale [DERS; Gratz & Roemer, 2004]). The bi-variate correlations are 
reported in Table 12. Descriptions of the post-hoc measures and their internal consistency in the current 
sample can be found in the Appendix.  
The DTS was was significantly negatively related to all of the post-hoc measures albeit to varying 
degrees: fear of detox (r = -.22, p < .01; shared variance = 5%), experiential avoidance (r = -.36, p < .01; 
shared variance = 13%), anxiety sensitivity (r = -.36, p < .01; shared variance = 13%), discomfort 
intolerance  (r = -.19, p < .05; shared variance = 4%), and emotion dysregulation (r = -.52, p < .01; shared 
variance = 27%). In contrast, the only significant association with the behavioral index of distress 
intolerance was anxiety sensitivity (r = -.20, p < .05; shared variance = 4%).  
Fear of detox was associated with three of the cannabis-related dependent measures: cannabis 
withdrawal, perceived barriers to cannabis cessation, and severity of cannabis problems (r’s range: .30-.61, 
p < .01). Fear of detox was also was significantly related to negative affect (r = .20, p < .05).  
Experiential avoidance was associated with four of the cannabis dependent measures: cannabis 
withdrawal, self-efficacy for quitting, perceived barriers to cannabis cessation, and severity of cannabis 
problems (r’s range: .19-.37, p < .05). Experiential avoidance also was significantly related to negative 
affect (r = .40, p < .01). 
Anxiety sensitivity was significantly related at the bi-variate level to cannabis withdrawal, self-
efficacy for quitting, perceived barriers to cannabis cessation, and severity of cannabis problems (r's range: 
.21-.49, p < .05). Anxiety sensitivity also was significantly related to negative affect (r = .34, p < .01). 
Discomfort intolerance was only associated with cannabis withdrawal (r = .25, p < .01). 
Discomfort intolerance was not associated with negative affect at the bivariate level.  
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Emotion dysregulation was associated with three of the cannabis-related dependent measures: 
cannabis withdrawal, perceived barriers to cannabis cessation, and severity of cannabis problems (r’s 
range: .26-.39, p < .01). Emotion dysregulation was also associated with negative affect (r = .54, p < .01). 
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CHAPTER 6: DISCUSSION 
The current study empirically evaluated perceived and behavioral distress intolerance among CUD 
and key aspects of the quit experience (e.g., problems in quitting, beliefs about barriers in quitting). 
Specifically, I examined the main and interactive effects of perceived and behavioral indices of distress 
intolerance in terms of (a) lifetime history of CUD quit success; (b) severity of withdrawal problems 
experienced while quitting and self-efficacy for abstaining from cannabis; and (c) severity of cannabis use 
problems among active users with CUD from diverse backgrounds. I first briefly discuss the nature of the 
sample recruited. I then present the key findings from the investigation and attempt to contextualize them 
relative to past work and possible explanatory factors for them. I thereafter discuss the results from post 
hoc tests, synthesize the findings across the analyses completed, and finally, present key limitations of the 
study and points for future study. 
6.1. Nature of the Sample 
The sample recruited was racially and ethnically diverse (65.2% minority) adult cannabis users. 
The majority of participants had not completed college (46.5%), and over 25% of the sample fell well-
below the 2013 Federal Poverty Level (FPL) threshold (FPL = $11,490; U.S. Department of Health and 
Human Services, 2015). In fact, the majority of the sample reported annual incomes between the FPL and 
$34,999 (43.2%) and only 18% of the sample indicated they were currently employed full-time. The 
sample had high rates of co-occuring psychiatric illness and medical disease. For example, 36.1% met 
criteria for a current anxiety disorder, 26.4% met criteria for a current mood disorder, and a little over half 
of the current sample endorsed one or more current medical conditions (notably, measured via a truncated 
list of medical problems). Overall, the sample was highly diverse, low-income, had low levels of 
educational attainment, was under-employed, and met criteria for a high number of psychological and 
medical conditions.  
Because the present study employed a descriptive design (one sample and no comparison group), I 
first attempted to benchmark the sample relative to past studies on distress intolerance and CUD (see Table 
1). Here, a number of observations warrant comment (see Table 13 for comparison study participant 
characteristics). First, five of the seven previous studies included samples with the vast majority identifying 
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as White or Caucasian (78.1-95.8%). Bujarski and colleagues’ (2012) study included 74% who identified 
their Nationality as Australian. Daughters and colleagues (2005) reported on the only underrepresented 
group (89.9% identified as African American), yet this study only included a behavioral measure of distress 
intolerance (PASAT; Lejuez, Kahler, & Brown, 2003), and none of the other measurements that were 
included in the current study. Second, four out of the seven previous studies included samples with a 
majority of female participants. In terms of education, only one study reported participant’s level of 
education, with the remaining studies either under-reporting (e.g., “sample consisted of undergraduates,” or 
“university recruitment”), or not reporting data on education (n = 3).  
With regard to substance use, 61% of the current sample reported cannabis use more than once per 
week, with the sample averaging 14.2 for total years of cannabis use. A little more than half of the sample 
reported current tobacco use (59.2%), but demonstrated low to moderate levels of nicotine dependence 
(Heatherton et al., 1990). In addition, 45% of the sample endorsed harmful patters of alcohol use (Saunders 
et al., 2006), with 59% of those participants endorsing concurrent tobacco use. The comparison studies 
reported wide variations in terms of cannabis use. For ease of comparison, sample characteristics of all 
studies, presented in Table 13, include percent of weekly cannabis users, when those data were available 
(weekly cannabis use ranged from 8-100%). Across the four studies that reported alcohol use, drinking 
averages within the samples were above normative cutoffs for non-clinical samples (Saunders et al., 2006; 
White & Labouvie, 1989), and thus, arguably largely consistent with the current sample. Tobacco use was 
underreported across comparison studies, with the only other study reporting similar rates of tobacco use 
(55.1%) to those that were observed in the current sample. This latter finding is also consistent with related 
research focused on cannabis-tobacco interplay (Lee, Budney, Brunette, Hughes, Etter, & Stanger, 2014). 
Similarly, only one other study, conducted within an in-patient recovery facility, reported concurrent 
weekly substance use (cocaine = 55%; opiates = 38%), which was much higher than what was observed in 
the current community sample (cocaine = 4.5%); presumably due to the treatment setting recruitment site. 
Lastly, no other studies employed breath holding as a measure of behavioral distress intolerance, yet most 
(n = 6) comparison studies utilized the DTS as a measurement of perceived distress tolerance, with total 
scores ranging from 0-3.65. Two studies reported lower levels of negative affectivity among their sample, 
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and one study demonstrated comparable levels (M = 17.27). Overall, relative the vast majority of past work 
on this topic, the present sample appears  to represent somewhat of  a group of CUD individuals by being 
more diverse and from a lower socioeconomic background. 
6.2. Primary Tests of Study Aims 
In regard to the primary study aims, there was no empirical support for the interactive or main 
effects of perceived (DTS) or behavioral (breath-holding duration) distress intolerance for any of the 
dependent variables (Aims 1-3). Although previous studies did not utilize the cannabis dependent measures 
in the current report, the lack of significant effects in the regression models was nonetheless surprising 
given previous work on the topic (focused largely on coping motives for cannabis use), including studies 
that employed the DTS (Table 1). That said, at the bi-variate level, there was some modest evidence of a 
'signal' for perceived distress intolerance for certain cannabis dependent variables. Specifically, perceived 
distress intolerance was significantly negatively related to cannabis withdrawal, perceived barriers to 
cannabis cessation, and severity of cannabis use problems; these effects ranged from small to moderate in 
effect size (Cohen, 1988). However, as noted from the outset, once adjusting for the tendency to experience 
negative affect, there was no 'incremental effect' of perceived distress intolerance with these dependent 
measures. Moreover, no other significant relations were observed for perceived distress intolerance and the 
other cannabis dependent variables. Similarily, there was no evidence at the bi-variate level for behavioral 
distress intolerance (indexed by breath-holding duration) being related to the dependent variables.  
The data from the primary study aims collectively suggest, at least among the present largely 
minority sample who had low income and limited education, neither perceived or behavioral distress 
intolerance related in a robust fashion with the cannabis dependent measures. Therefore, one (conservative) 
interpretation of these findings is that distress intolerance may not perform the same way across all CUD 
samples. Although highly speculative, the increased exposure to multiple stressors associated with low 
socioeconomic environments (e.g., violence, low social cohesion, high unemployment) may be related to a 
distinct etiology of distress intolerance. For example, persons from lower socioeconomic environments 
may indeed have to be more tolerant of higher levels of and multi-level stressors that are inherent to many 
of such contexts, and therefore, this construct may not relate in the same manner (or strength) with 
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substance use behavior such as cannabis. One potentially fruitful next step would to explore the nature of 
distress tolerance (measured from a multi-method framework) as a function of varying levels of 
socieconomic levels and other social determinants of health (e.g., subjective social status, financial strain). 
It also may be useful to explore whether distress intolerance interplays with social determinants of health, 
which characterize many low income environments, for cannabis use behavior and even other forms of 
substance use. In fact, there is some evidence that related transdiagnostic constructs, such as anxiety 
sensitivity, may exacerbate the influence of social determinants of health (e.g., subjective social status) in 
relation to poorer mental health among underrepresented and low income groups (e.g., Latinos; Zvolensky 
et al., in press). Drawing from such work, it is conceivable that distress intolerance may similarly interact 
with social determinants of health in relation to substance use behavior among health disparity groups, such 
as the one recruited for the present study. Additionally, as I measured only two types of distress intolerance 
(DTS and breath-holding duration), it is not possible to assume similar relations (or lack thereof) would be 
evident for other types of distress intolerance described in theoretical (Zvolensky et al., 2010) and emprical 
(Bardeen et al., 2013) models of the construct. Therefore, exploration of other distress intolerance 
constructs in the hierarchical model would be a useful next research step. Another non-mutually exclusive 
possible explanation may center on the level of understanding of what distress tolerance 'means' among the 
sample studied (i.e., comprehension of the written items) for the perceived distress intolerance construct. 
To better understand this type of issue, qualitative research on distress intolerance may be useful to help 
clarify what this constructs represents among underrepresented groups, especially those with limited 
education and lower socioeconomic status. 
Although not a primary study aim, a number of other points related to the primary aims warrant 
comment. First, there was no significant association between perceived distress intolerance and behavioral 
distress intolerance. This finding is consistent with past work that has examined interrelations between 
perceived and behavioral indicators of distress intolerance (Bernstein et al., 2011; McHugh et al., 2011). 
Therefore, while theoretically related, the variables are empirically not interrelated at the bi-variate level.  
Future work is needed to continue to unravel the nature and interrelation between perceived and behavioral 
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distress intolerance and what these associations (or lack thereof) mean to theoretical models of the 
construct.  
Within this same context, there also should be more direct mention of the measurement of the 
distress intolerance measures. Specifically, the DTS appeared to perform largely as expected. Specifically, 
the internal consistency of the total score, and to lesser extent subscales, was excellent to adequate, it 
maintained convergent validity with negative affect and other transdiagnostic tolerance-related constructs, 
and showed (some) expected relations with certain cannabis dependent measures.  There also appeared to 
be adequate variability in the measure among the present sample when benchmarked to previous cannabis 
studies using this assessment device. These data collectively lend credibility to the DTS as a measure of 
perceived distress intolerance among the present sample.    
 In line with past work, breath-holding trials were highly interrelated (Bernstein, Trafton, Ilgen, 
& Zvolensky, 2008). This finding is consistent with past work that has found breath holding duration to be 
highly reliable over short and longer periods of time (e.g., a one-year time period) and generally 
comparable to the stability observed for personality characteristics (e.g., Groth-Marnat & Mullard, 2010) 
and certain physiologic measures (e.g., heart rate variability; Bertsch et al., 2012). Additionally, although 
past work has found breath holding duration to maintain unique explanatory value in relation to other 
behavioral distress tolerance measures (Hogan et al., 2014), smoking cessation outcomes (Hajek, 1991) and 
lapse behavior (Kahler, McHugh, Metrik, Spillane, & Rosenow, 2013), relapse risk in gambling (Daughters 
et al., 2005), and fear reactivity to bodily sensations (Asmundson & Stein, 1994; Eifert, Zvolensky, Sorrell, 
Hopko, & Lejuez, 1999; Roth, Wilhelm, & Trabert, 1998), this measurement may also tap other features 
that do not exclusively align with distress tolerance processes. For example, some work has found cognitive 
processes related to threat interpretation are related to breath holding duration (Brandt, Johnson, Schmidt, 
& Zvolensky, 2012; Eke & McNally, 1996); data fully consistent with the negative bi-variate relations with 
anxiety sensitivity observed in the current report. Other studies have found breath-holding duration is not 
related to performance on neurobehavioral tests loading on cognitive and/or behavioral inhibitory resources 
(Sutterlin et al., 2013); presumably, a prerequisite for a process that involves an active and effortful 
withstanding of stressful states (Alpher & Blanton, 1991). Moreover, breath holding duration has not 
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always been a consistent predictor of substance use or emotional vulnerability (Zvolensky, Feldner, Eifert, 
& Brown, 2001). The present study naturally cannot fully address the validity of breath holding duration as 
a behavioral measure of distress intolerance. However, there was little association with this measure at the 
bi-variate level with other distress intolerance processes, medical problems, and no notable relations to the 
cannabis dependent measures (the latter not necessarily being the best indicator of validity because of the 
lack of research on this topic).  Future work is needed to further elucidate the underpinnings of breath 
holding duration to better understand its potential role in models of distress intolerance and its clinical 
correlates, such as substance use behavior. 
Second, negative affect was consistently significantly associated with several of the cannabis 
dependent measures, including withdrawal symptoms, self-efficacy for quitting cannabis, perceived barriers 
for cannabis cessation, and cannabis use problems. The effect sizes were moderate in size, suggesting some 
degree of potential thoeretical and clinical significance. At the same time, there was no direct relation 
between negative mood and other cannabis use variables focused on quit length or attempts, an issue 
perhaps influenced, in part, by the retrospective recall of (past) quit behavior. These data are nonetheless 
generally consistent with a large empirical literature linking negative mood states and psychopathology 
(anxiety/depressive conditions) and CUD (e.g., Agosti et al., 2002; Arendt & Munk-Jorgensen, 2004; 
Bovasso, 2001; Budney et al., 1998; Copeland et al., 2001; Miller, Klamen, Hoffmann, & Flaherty, 1996; 
Rey et al., 2002; Zvolensky, et al., 2006). Yet, to the best of my knowledge, the present data extend such 
work to cannabis use variables not previously studied in relation to negative mood (i.e., self-efficacy for 
quitting cannabis and perceived barriers for cannabis cessation). These data continue to highlight the close 
interconnection between negative mood and substance use disorders generally. There is an obvious need to 
continue to explore the time course and patterning of relations between negative mood and CUD using 
prospective and laboratory (experimental) methodologies.  
6.3. Post Hoc Tests 
I conducted post hoc tests due to the lack of empirical support for the primary study aims. As with 
any post hoc test, these results should be considered with caution, as they are, by definition, exploratory in 
nature. The first set of analyses focused on the subscales of the perceived distress intolerance construct and 
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the cannabis dependent measures. As noted in the Results Section, the underlying logic was that it is 
possible that for perceived distress intolerance, specific subfactors may maintain stronger relations to the 
dependent variables than the total score (i.e., specific facets of distress tolerance may showcase stronger or 
weaker relations to particular cannabis use variables). Results indicated the absorption subscale was 
significantly negatively related to the most cannabis dependent measures (n = 3; cannabis withdrawal, 
perceived barriers to cannabis cessation, and cannabis use problems), although all of the subscales were 
related to at least two dependent measures (i.e., cannabis withdrawal and perceived barriers to cannabis 
cessation). None of the four perceived distress intolerance subscales were associated with lifetime quit 
index, longest abstinence duration, or abstinence duration during most recent quit attempt.  The subsequent 
regression analyses attempted to examine the DTS subscales incremental association relative to negative 
affectivity with the cannabis dependent measures wherein a significant bi-variate relation was detected. 
None of these models provided empirical support for a direct relation (incremental) for the cannabis 
dependent measures. These findings, in conjunction with those from the primary study aims, continue to 
provide little to no empirical support for a direct relation between perceived distress intolerance and the 
studied cannabis dependent measures among the current sample.  
The second series of post hoc tests were theoretically-oriented on an indirect effect. Specifically, 
the potential explanatory role of negative affect in the association between perceived distress intolerance 
and cannabis dependent variables was completed. These tests focused on only those cannabis dependent 
measures wherein there was a significant bi-variate relation between negative affect and a specific cannabis 
variable; namely, cannabis withdrawal, self-efficacy for quitting, perceived barriers to cannabis cessation, 
and severity of cannabis use problems. Greater levels of perceived distress intolerance were predictive of 
higher levels of cannabis withdrawal symptoms, lower self-efficacy for quitting, and higher perceived 
barriers to cannabis cessation, indirectly, through greater levels of negative affect. However, confidence 
intervals for models that included severity of cannabis use problems were inclusive of zero. Therefore, 
mediation was not observed (Hayes, 2013).”  
Alternative models, used to explore the findings due to the cross sectional nature of the data, 
supported a simple explanatory  model for the indirect effects of perceived distress intolerance for self-
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efficacy for quitting cannabis through the presence of negative mood. In regard to withdrawal symptoms 
and perceived barriers to cannabis cessation, the alternative models suggested a putative bi-directional 
relation between negative affect and these cannabis dependent variables.  Specifically, these data suggest 
that one’s perception about their to manage distressing or aversive stimuli (greater perceived distress 
intolerance) may, in turn, be related to greater cannabis withdrawal symptoms and perceived barriers to 
quitting  in the context of higher levels of negative affect. However, this relation is apt to be bi-directional 
nature (Warner, 2012). Overall, the tests of model specificity suggest potentially complex relations between 
perceived distress intolerance and the studied cannabis dependent variables. It is possible that future 
research would benefit by using time sampling tactics to further probe the relations between perceived 
distress intolerance and cannabis variables, such as those studied here, over the course a specific epoch of 
time (e.g., two weeks) or during a designated quit attempt.  
 A final set of bi-variate relations were computed between other transdiagnostic, tolerance-related 
constructs and the cannabis dependent measures. This series of post hoc analyses were aimed at placing 
some broader 'explanatory parameters' on the distress intolerance variables that were modeled by relating 
them to other variables that may serve similar functions. For perceived distress intolerance, there were, as 
would be expected and found in past work, significant bi-variate relations to fear of detox, experiential 
avoidance, anxiety sensitivity, discomfort intolerance, and emotion dysregulation (Leyro et al., 2010). The 
strongest interrelation was between perceived distress intolerance and emotion dysregulation, which may 
partially be due to overlapping item content for the emotional non-acceptance subscale of the DERS (Gratz 
& Roemer, 2004). These data would be consistent with convergent (concurrent) validity of the DTS. Yet, 
the only significant association with the behavioral index of distress intolerance was anxiety sensitivity; a 
finding in line with past work (Asmundson & Stein, 1994), and perhaps, reflective of the more narrow 'fear 
of internal somatic perturbation' arguably at the center of the anxiety sensitivity construct (McNally, 2002). 
These data also could be considered in line with discriminant and convergent (concurrent) validity of 
breath-holding duration in the current CUD sample. Overall, the bi-variate relations between perceived and 
behavioral distress intolerance and related tolerance constructs were consistent  with expectation and lends 
some further empirical credability to their construct validity among the present sample. 
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The related transdiagnostic tolerance variables showcased largely similar, but not fully uniform, 
relations to the cannabis dependent measures. Specifically, all the measures, with the sole exception of 
discomfort intolerance, were significantly related to cannabis withdrawal and perceived barriers for 
cannabis cessation.  Experiential avoidance, anxiety sensitivity, and emotion dysregulation each were 
additionally related to self-efficacy for quitting and severity of cannabis use problems in the expected 
direction. No variables were related to quit attempts or duration of time in quitting. Because there is still 
relatively little work on many of these transdiagnostic constructs  among CUD populations (e.g., Johnson, 
Mullin, Marshall, Bonn-Miller, & Zvolensky, 2010), these data may therefore usefully prompt scholars to 
explore the relative utility of these factors in the maintenance and relapse of cannabis processes in future 
work. Here, it may be useful to continue to model multiple manifest indicators of distress intolerance and 
related transdiagnostic variables in one model rather than focus exclusively on one of these variables 
(Ameral, Palm, Cameron, & Armstrong, 2014). Indeed, there is some preliminary empirical evidence that 
stress sensitivity and tolerance may be hierarchically arranged (e.g., Bernstein, Zvolensky, Vujanovic, & 
Moos, 2009; McHugh & Otto, 2011). 
6.4. Clinical Implications 
 In the abscence of direct support for the primary study aims, there is arguably little clinical 
implication of the distress intolerance factors studied for the cannabis dependent measures studied among 
the population that was sampled. Yet, perceived distress intolerance showcased some consistent bi-variate 
relations with  cannabis withdrawal, perceived barriers to cannabis cessation, and severity of cannabis use 
problems. These small to moderate effects, in conjunction with the observed relations to negative mood, 
suggest it may be useful to assess perceived distress tolerance (measured via the DTS) among CUD 
populations because it is related to certain cannabis use processes and could be targeted in intervention 
programming. That said, post hoc analyses revealed similar, and even stronger relations in certain cases, for 
these same (and other variables) in terms of other transdiagnistic affective vulnerability processes, such as 
fear of detox, experiential avoidance, and anxiety sensitivity. As noted in the preceding section, these data 
may suggest future work may be better suited to explore these other  affective vulnerability processes in 
CUD research/practice, an area of work which is, in fact, starting to occur for certain variables such as 
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experiential avoidance (e.g., Buckner, Zvolensky, Farris, & Hogan, 2014) and anxiety sensitivity (e.g., 
Zvolensky et al., 2006; Zvolensky et al., 2009).  
 Perhaps the most interesting clinical implication for perceived distress intolerance centers on the 
indirect post hoc analyses. These data suggest, at least for perceived distress intolerance, scholars could 
usefully consider its relation to negative affect and vice versa to better understand the nature of cannabis 
use processes. To the extent distress intolerance is directly or indirectly related to cannabis use variables via 
negative affect, targeted interventions that seek to reduce distress intolerance and negative emotional states 
would be important to facilitate change in cannabis processes. Also, even if bi-directional relations exist 
between perceived distres intolerance and negative affect (which is apt to be the case), interventions 
addressing these variables in a coherent theoretical model may be useful to consider. Interestingly, there is 
some work starting to integrate distress intolerance in substance use treatment. As one example, 
Bornovalova and colleagues (2012) developed a brief distress intolerance intervention (Skills for 
Improving Distress Intolerance; SIDI), as an adjunctive therapy for low-income, mostly minority (90% 
African American) patients receiving care at a residential substance treatment program. The SIDI 
intervention included an emotional exposure component, allowing patients to practice skill development 
and ability to tolerate emotional experiences in the context of negative mood (Bornovalova et al., 2012). 
Bornovalova (2012) found that the two comparison treatment groups that the SIDI intervention was tested 
against both demonstrated similar reductions in negative mood during the course of treatment to the SIDI 
group. Yet, the SIDI group was the only condition that showed a significant reduction in their behavioral 
distress intolerance (mirror-tracing task; Strong et al., 2003; PASAT; Lejuez, Kahler, & Brown, 2003). 
Because this study employed behavioral distress intolerance measurement with a monetary incentive for 
task persistence (Bornovalova et al., 2012) and did not measure perceived distress intolerance, the extent to 
which it can be compared to the current sample is unclear. Yet, it provides one illustration of a type of 
treatment model that addresses distress intolerance substance use behavior. Related types of work have 
similarily focused on improving  distress intolerance via emotional acceptance in treatment paradigms for 
tobacco (Brown et al., 2013; Zvolensky, Bogiaizaian, Salazar, Farris, & Bakhshaie, 2014). Other non-
addictive oriented treatment studies have reported that increases in distress intolerance during treatment for 
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mood/anxiety disorders are related to better clinical outcomes (McHugh, Kertz, Weiss, Baskin-Sommers, 
Hearon, & Bjorgvinsson, 2014; Williams, Thompson, & Andrews, 2013).  
6.5. Study Limitations and Future Directions 
There are several limitations not already noted that warrant comment. First, the current 
investigation was cross-sectional in design and represents a 'snap-shot' of the relations observed among the 
present sample. Due to the design, the direction and causal nature of the predictor and dependent variables 
cannot be interpreted within the context of the current study. As noted earlier, future work might examine 
these relations prospectively to elucidate the directional effects of the observed relations. Second, some the 
findings from the current study may have been influenced by shared method variance as a result of utilizing 
self-report measures to assess the main study constructs (although not all). Outside of additional 'multi-
method approaches' (which were employed), field and laboratory assessment of distress intolerance or 
experimental manipulation of the construct  may be particularly informative. For example, scholars could 
explore how distress intolerance relates prospectively to time to first cannabis lapse using time sampling 
methods during an actual quit attempt, or inversely, how distinct periods of cannabis deprivation (e.g., no 
use for 24 hours, no use for 12 hours, no use for 6 hours) relates to distress intolerance across a range of 
laboratory tests that vary in the content of distress (e.g., pain versus frustration versus arousal). Third, the 
assessment of cannabis withdrawal cannot be understood to be a 'pure index' of withdrawal because there 
was no measurement of change in withdrawal symptoms. In all likelihood, the cannabis withdrawal 
measure, as employed here, taps the report of negative affect and cannabis withdrawal symptoms. Future 
research could usefully build upon this work by exploring distress intolerance when measuring withdrawal 
in the context of cannabis use in quit paradigms or laboratory protocals that manipulate duration of 
abstinence from cannabis use.  
Fourth, because of the low educational levels of the sample, there is a possible concern (briefly 
noted earlier) about level of comprehension/understanding of the assessment material. I did not formally 
measure reading level, and therefore, it is not possible to explicate the nature of this possible issue. Future 
work would benefit from addressing this matter in order to more comprehensively examine the role of 
distress intolerance in cannabis use behavior. Fifth, there was a larger number of males relative to females 
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in the sample. The reason for this selection bias is not clear. Future work may usefully sample males and 
females at an equivalent proportion to better gauge the applicability of distress intolerance to 
males/females. Also related to generalizability, because the sample was from underrepresented groups and 
lower socioeconomic levels, applicability to other social strata segments and ethnic groups may not be 
possible. Studies could possibly move the field forward further by modeling distress intolerance across 
different socicultural and socioeconomic segments of the cannabis using population in future work to 
address this matter, as it is not likely cannabis use (or, other substance use) functions the same across 
individuals. Indeed, the combination of social inequities that diminish access to reward with inherent 
limitations in reward responsivity (characteristic of drug using populations) may produce increases in the 
motivation to use cannabis to obtain reinforcement. Therefore, the 'reinforcing nature of cannabis' may vary 
as a function of socieconomic status or social determinants of health. Sixth, there was no biochemical 
assessment of cannabis use and related substance use. Cannabis use behavior has many different facets 
(e.g., amount, quality, method of consumption). Although self-report measures for frequency and quantity 
of cannabis use are currently employed widely, continued efforts to strengthen measurement of cannabis 
use is paramount. Researchers are currently testing alternative methods for quantifying self-reported 
cannabis use (Norberg, Mcakenzie, & Copeland, 2011). Future studies could minimally incorporate 
biochemical 'verification' to cross-index its relation to self-reported use.  
Seventh, I employed a modified version of a perceived barriers to cannabis cessation scale 
(adapted from tobacco research) to index perceptions of barriers related to quitting cannabis. This construct 
represents a novel area of cannabis research, but results from this measure should be considered in light of 
the fact that this scale, unlike the others employed, has not been tested in a psychometrically rigorous 
fashion yet. That said, the scale did appear to perform largely as expected by showcasing consistent 
significant relations to some of the other cannabis use variables (see Table 5; cannabis use problems) and 
demonstrating a high level of internal consistency. Future work could possibly examine the potential 
explanatory utility of perceived barriers for cannabis cessation in treatment or self-quit paradigms after 
further psychometric development/testing (e.g., factor analysis, test-retest reliability). Eighth, for the 
measurement of physical health problems, I relied on a brief checklist from our team that lists only some of 
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the more common medical problems in studies of substance use that may be contraindicated for 
participation in laboratory studies in our research. Outside of the validity of self-reporting medical 
problems (people may be unaware of certain conditions, confuse them with other disorders, etc.), there is a 
truncated range for endorsement. Given the high rate of endorsement for the problems listed, it may prompt 
scholars to further explore the interplay of medical disease with affective vulnerability processes in the 
context of CUD. Here, syndemic models, which seek to explore relations between substance use, physical 
health, and mental health problems, contributing to excess burden of disease, could be a useful method of 
guidance. In other words, examining the synergistic effect of the presence of multiple-morbidities, as was 
evident in the current sample, may help inform clinical interventions to improve and provide health care 
among unique sub-sets of the population at greater risk for poor health outcomes (Gonzalez-Guarda, & 
Florom-Smith, 2011). Ninth, also related to measurement, the FTND had low levels of internal consistency; 
an issue often apparent with this measure (Korte, Capron, Zvolensky, & Schmidt, 2013). Yet, Cronbach 
alpha values are fairly sensitive to the number of items in each scale and it is not uncommon to find lower 
Cronbach values with shorter scales (e.g., scales with less than 10 items, such as the six-item FTND 
(DeVellis, 2003). 
Tenth, as noted at the outset of the post hoc test section of the Discussion, I ran many analyses to 
further explore the data in the absence of support for the main hypotheses. Although exploratory efforts 
such as these are often useful in generating new insights into the phenomena under study, they come with 
an inherent cost: the uncorrected number of tests yields a risk of interpretative error (Type I error). The best 
approach for future study would therefore be to use the results from the post hoc tests as a 'starting point' 
for an a priori test(s) and novel data collection. Eleventh, I measured a relatively broad range of cannabis 
dependent variables. That said, I did not measure all possible cannabis change or quit processes. Future 
work could continue to explore distress intolerance in relation to other cannabis use processes, such as 
craving, motivation to quit, outcome expectancies, reward sensitivity, and related constructs. Finally, it is 
worth noting that the quit duration variables (total lifetime quit attempts, longest abstinence duration ever 
achieved, or abstinence duration during the most recent quit attempt) were not related in a robust fashion 
with any of the other primary predictor or dependent variables (including other cannabis use variables). 
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These findings prompt broad-based caution in the validity of these variables. It may simply be to 
challenging for an individual, especially a person with CUD, to recall in a reliable and valid way their quit 
history. To address this matter, prospective modeling of quit behavior will be necessary.  
6.6. Summary 
The present study explored perceived and behavioral distress intolerance factors in relation to an 
array of cannabis use variables among a CUD sample who was highly diverse, low-income, had low levels 
of educational attainment, and high levels of psychological and medical problems. The study was designed 
to build off past work and provide a novel test of an interactive model. The work sits on the backdrop of  
emerging efforts in the substance use disorder field to isolate transdiagnostic affective vulnerability 
processes that may undergrid problematic substance use behavior and its co-occurrence with 
psychopathology (Leventhal & Zvolensky, 2015). Yet, the present results yielded no empirical support for 
the synergistic effect of perceived and behavioral distress intolerance factors in relation to the studied 
cannabis use variables among the studied sample. Although several caveats, detailed earlier, suggest some 
degree of caution to be placed in these (null) findings, post hoc tests suggested potentially clinically and 
theoretically interesting effects. Perhaps most notably, the explanatory role of negative mood in the context 
of perceived distress intolerance and certain cannabis variables highlights the general importance of 
understanding the interconnection between negative affect, tolerance for distress, and substance use 
disorders. Future theory-driven work that seeks to uncover the time course and patterning between distress 
intolerance, negative mood, and cannabis use behavior are needed. In such a pursuit, it will likely remain 
imperative to consider the social context of affective vulnerabilities processes in relation to cannabis use 
behavior and the multiple types of health and psychological problems that often characterize health 
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Table 1: Summary of studies examining distress intolerance and cannabis 
 Study Characteristics Measures of distress 
intolerance 
Summary of major 
findings 
Daughters et al., 2005 (n = 89; 37.1% male Mage = 
39.2, SD = 9.4; years; 89.9% 
African American) 
Paced Auditory Serial 
Addition Task (PASAT; 
Gronwall, 1977; Lejuez, 
Kahler, & Brown, 2003) 
 
Results suggest that duration 
of substance abstinence is 
related to persistence on the 
distress intolerance task. 
Simons & Gaher, 2005 (n = 642; 70% female; Mage = 
19.90, SD = 1.64; 89% 
Caucasian, 7% African 
American, 1% Asian, 1% 
multiracial, 2% other) 
Distress Tolerance Scale 
(DTS; Simons & Gaher, 
2005) 
Findings suggest that those 
who endorse high levels of 
distress intolerance have an 
increased concurrent 
likelihood to use these 
substances (alcohol and 
cannabis) because they 
believe it can help reduce 
negative affect.  
Buckner et al., 2007 (n = 265; 63.3% female; Mage 
= 18.7 SD = 1.2; 78.1% 
Caucasian)  
Distress Tolerance Scale 
(DTS; Simons & Gaher, 
2005) 
Discomfort Intolerance Scale 
(DIS; Schmidt et al., 2006) 
 
Results indicated that 
distress intolerance is 
significantly associated with 
increased problems 
associated with alcohol and 
cannabis use, as well as 
increased cannabis use 
frequency. 
Zvolensky et al., 2009 (n = 135; 46.7% women; Mage 
= 20.45, SD = 5.0; 95% 
Caucasian, .7% African-
American, .7% Asian, .7% 
Hispanic, .7% bi- or 
multiracial, 1.5% other) 
Distress Tolerance Scale 




Sanderson, Rapee, & 
Barlow, 1988, 1989) 
 
Results suggest that 
perceived distress 
intolerance is uniquely 
concurrently related to 
coping-oriented cannabis 
use. 
Potter et al., 2011 (n =142; 46.5% women; 
Mage = 22.18, SD = 7.22; 
95.8% Caucasian, 0.7% 
Asian, 0.7% Hispanic/Latino, 
and 1.4% “other”) 
Distress Tolerance Scale 
(DTS; Simons & Gaher, 
2005) 
 
Results suggest that those 
who endorse a lower 
perceived ability to 
withstand emotional distress 
may experience higher levels 
of posttraumatic stress 
symptoms, and as a result, 
use cannabis to manage 
emotional distress. 
Bujarski et al., 2012 (n =118; 33.9% women; 
Mage = 29.84, SD = 12.41; 
74% reported Australia as 
their country of birth) 
Distress Tolerance Scale 
(DTS; Simons & Gaher, 
2005) 
Results suggest that 
individuals who are highly 
intolerant of distress may 
experience more problematic 
patterns of cannabis use. 
Dvorak et al., 2014 (n =817; 64.5% women; 
Mage = 20.14, SD = 2.36; 
92.04% Caucasian, 3.79% 
Asian, 1.22% African 
American, and 2.95% 
“other”) 
Distress Tolerance Scale 
(DTS; Simons & Gaher, 
2005) 
UPPS-P Impulsive 




intolerance compared with 
behavioral impulsivity, was 
related to more problems 
related to marijuana use, 
rather than frequency or 
quantity of use, which was 









Table 2: Inclusionary and Exclusionary Criteria 
 
Criteria Included Excluded 
Between the ages of 18-65 
 
X  
Current diagnosis of cannabis 
abuse or dependence 
X  
Active cannabis user (e.g., use 
three days/per week) 
X  
Two or more cannabis quit 
attempts, with at least one 
occurring in the past year 
X  
Ability to give informed, 
voluntary, written consent 
X  














Legal mandate limiting 
cannabis use, related to 
reported quit attempt 
 X 





















Table 3: Measure Administration Schedule 




Screening/Cannabis History    
Marijuana History Questionnaire x x Dependent variable 
Demographics Questionnaire  x Covariate 
Medical Problems x x Descriptive measure  
SCID-NP  x Used to determine 
eligibility 
Motives/Quit Strategies    
Self-efficacy for Quitting  x Dependent variable 
Marijuana Problems Scale  x Dependent variable 
Barriers to Cannabis Cessation  x Covariate 
Marijuana Withdrawal Checklist  x Dependent variable 
Psychological Symptoms    
Positive and Negative Affect Scale  x Covariate 
Distress Intolerance    
Distress Tolerance Scale  x Primary predictor  
variable 
Breath-Holding Task  x Primary predictor 
variable 
Related Distress Intolerance Constructs 
(Post-hoc) 
   
Detox Fear Survey Schedule-27  x Post-hoc Comparison 
Multidimensional Experiential Avoidance 
Questionnaire 
 x Post-hoc Comparison 
Anxiety Sensitivity Index III  x Post-hoc Comparison 
Discomfort Intolerance Scale  x Post-hoc Comparison 
















Table 4: Rates of Psychopathology and Physical Illness 
 
PSYCHOPATHOLOGY  Total Percent % 
 Anxiety Disorders   
 Posttraumatic Stress Disorder 33 21.3% 
 Specific phobia 8 5.2% 
 Generalized Anxiety Disorder 5 3.2% 
 Social Anxiety Disorder 4 2.6% 
 Panic Disorder 3 1.9% 
 Obsessive-compulsive Disorder 1 0.6% 
 Anxiety disorder not otherwise 
specified 
2 1.3% 
    
Total = 36.1% 
    
 Mood Disorders   
 Dysthymia 9 5.8% 
 Bipolar I/II 7 4.5% 
 Major Depressive Disorder 25 16.1% 
    
Total = 26.4% 
    
 Substance Use Disorders   
 Alcohol Use Disorder 21 13.5% 
 Cocaine Use Disorder 7 4.5% 
    
Total = 18% 
    
    
PHYSICAL ILLNESS    
 Medical Conditions   
 Respiratory Conditions 55 35.5% 
 Head Injury 18 11.6% 
 Diabetes 9 5.8% 
 Heart Problems 3 1.9% 
 Hypertension 25 16.1% 





























Notes: * = p < 0.05; ** = p < 0.01. Poly substance = concurrent regular use of tobacco, alcohol or other 
substances (coded as, no other substance use = 0, or, other concurrent substance use = 1); Respiratory 
Condition  = presence of a respiratory condition, including asthma, chronic bronchitis, allergies (coded 0 = 
no condition, or 1 = one or more conditions endorsed); NA = Positive and Negative Affect Scale – 
Negative Affect subscale (Watson et al., 1988); Gender = sex participant identified with, percent listed is 
female (coded as, female = 0, or, male = 1); DTS = Distress Tolerance Scale Total Score (Simons & 
Gaher, 2005); BHT= latency to end the 2nd trial of the breath holding task (Asmundson & Stein, 
1994)Lifetime Quit Index = total number of lifetime quit attempts; Longest Quit Duration = duration in 
days of longest abstinence period ever achieved; Recent Quit Duration = duration in days of most recent 
abstinence period; MWC = Marijuana Withdrawal Checklist – Total Score (Budney et al., 1999); SEQ = 
Self-Efficacy Questionnaire – Total Score (Marlatt & Gordon, 1985); BCCS = Barriers to Cannabis 
























































           
3. NA 19.72(8.19) 
4-46/4-46 -.01 .20* -- 













         












        












































































































   




















































































Table 6: Hierarchical regression models for Aim 1  
 
Model 1: Lifetime Quit Index 
 R R2 R2 change Coeff. † SE t 
Step 1 .14 .02     
Perceived Distress 
Intolerance 




   .02 .03 .61 
Step 2   .01    
Perceived * 
Behavioral 
   -.00 .00 -.93 
Model 1: Longest Quit Index 
 R R2 R2 change Coeff. † SE t 
Step 1 .15 .02     
Perceived Distress 
Intolerance 




   .01 .01 1.16 
Step 2   .01    
Perceived * 
Behavioral 
   -.00 .00 -1.35 
Model 1: Recent Quit Index 
 R R2 R2 change Coeff. † SE t 
Step 1 .13 .02     
Perceived Distress 
Intolerance 




   .02 .01 1.45 
Step 2   .01    
Perceived * 
Behavioral 
   -.00 .00 -1.45 
Notes: *p < .05, **p < .01, † = unstandardized regression coefficient  Lifetime Quit Index = total number of 
lifetime quit attempts; Longest Quit Duration = duration in days of longest abstinence period ever achieved; 
Recent Quit Duration = duration in days of most recent abstinence period; Perceived Distress Intolerance = 
Distress Tolerance Scale – Total Score (Simons & Gaher, 2005); Behavioral Distress Intolerance = latency 
(duration) to end the second trial of the breath holding task (Asmundson & Stein, 1994); Perceived * 














Table 7: Hierarchical regression models for Aim 2 
Model 1: Cannabis Withdrawal (MWC) 
 R R2 R2 change Coeff. † SE t 
Step 1 .42 .17**     
Gender    -5.81 3.16 -1.84 
NA    .62** .18 3.41 
Respiratory    2.77 2.99 .93 








   -.17 .03 .61 
Step 3   .01    
Perceived * 
Behavioral 
   -.00 .00 .64 
Model 1: Self-Efficacy for Quitting (SEQ) 
 R R2 R2 change Coeff. † SE t 
Step 1 .24 .06*     
NA    .45* .19 2.39 








   -.01 .21 -.07 
Step 3   .00    
Perceived * 
Behavioral 
   -.00 .00 -.42 
Model 1: Barriers to Cannabis Cessation (BCCS) 
 R R2 R2 change Coeff. † SE t 
Step 1 .38 .14**     
Gender    -3.50 2.32 -1.51 
NA    .46** .14 3.33 








   .07 .16 .43 
Step 3   .00    
Perceived * 
Behavioral 
   -.00 .00 -.32 
Notes: *p < .05, **p < .01, † = unstandardized regression coefficient. MWC = Marijuana Withdrawal 
Checklist (Budney et al., 1999); SEQ = Self-Efficacy Questionnaire (Marlatt & Gordon, 1985); BCCS = 
Barriers to Cannabis Cessation Scale; Gender = sex participant; NA = Positive and Negative Affect Scale – 
Negative Affect subscale (Watson et al., 1988); Respiratory = respiratory condition; Perceived Distress 
Intolerance = Distress Tolerance Scale (Simons & Gaher, 2005); Behavioral Distress Intolerance = breath 




 Table 8: Hierarchical regression models for Aim 3  
 
Model 1: Cannabis Problems (MPS) 
 R R2 R2 change Coeff. † SE t 
Step 1 .37 .13**     
NA    .00** .00 4.11 








   -.00 .00 -.89 
Step 3   .00    
Perceived * 
Behavioral 
   .00 .00 .85 
Notes: *p < .05, **p < .01, † = unstandardized regression coefficient. MWC = Marijuana Withdrawal 
Checklist (Budney et al., 1999); SEQ = Self-Efficacy Questionnaire (Marlatt & Gordon, 1985); BCCS = 
Barriers to Cannabis Cessation Scale; Gender = sex participant; NA = Positive and Negative Affect Scale – 
Negative Affect subscale (Watson et al., 1988); Respiratory = respiratory condition; Perceived Distress 
Intolerance = Distress Tolerance Scale (Simons & Gaher, 2005); Behavioral Distress Intolerance = breath 

















Table 9: Bivariate Correlations between Subscales of Perceived Distress Intolerance and Dependent 
Variables 
 




            










































































19-57/19-53 -.17* -.21** -.15 -.08 -.12 .11 .07 .04 .40** .17* 
.44
** -- 
Notes: * = p < 0.05; ** = p < 0.01. DTS Total Score= Distress Tolerance Scale – Total Score (Simons & 
Gaher, 2005); DTS Absorption= Distress Tolerance Scale – Absorption Subscale (Simons & Gaher, 2005); 
DTS Appraisal= Distress Tolerance Scale – Appraisal Subscale (Simons & Gaher, 2005); DTS Regulation= 
Distress Tolerance Scale – Regulation Subscale (Simons & Gaher, 2005); DTS Tolerance = Distress 
Tolerance Scale – Tolerance Subscale (Simons & Gaher, 2005); Lifetime Quit Index = total number of 
lifetime quit attempts; Longest Quit Duration = duration in days of longest abstinence period ever achieved; 
Recent Quit Duration = duration in days of most recent abstinence period; MWC = Marijuana Withdrawal 
Checklist – Total Score (Budney et al., 1999); SEQ = Self-Efficacy Questionnaire – Total Score (Marlatt & 
Gordon, 1985); BCCS = Barriers to Cannabis Cessation Scale – Total Score; MPS = Marijuana Problems 
Scale – Total Score (Stephens et al., 2000). 
 
 
Table 10: Hierarchical regression analyses for post-hoc tests 
Model 1: Cannabis Withdrawal (criterion) 
 R R2 R2 change B SE β t 
Step 1 .34 .12**      
Negative 
Affectivity 
   .74 .16 .34** 4.48 
Step 2 .38 .14 .02     
DTS 
Absorption 
   -.77 .71 -.15 -1.08 
DTS 
Appraisal 
   .14 .43 .05 .34 
DTS 
Regulation 
   -.89 .74 -.13 -1.20 
DTS 
Tolerate 
   .34 .57 .07 .60 
Model 2: Cannabis Problems (criterion) 
 R R2 R2 change B SE β t 
Step 1 .34 .12**      
Negative 
Affectivity 
   .00 .00 .34** 4.43 
Step 2 .36 .13 .01     
DTS 
Absorption 
   -.01 .00 -.19 -1.38 
DTS 
Appraisal 
   .00 .00 .09 .69 
DTS 
Regulation 
   .00 .00 .05 .45 
DTS 
Tolerate 
   .00 .00 .01 .08 
Model 3: Barriers to Cannabis Cessation (criterion) 
 R R2 R2 change B SE β t 
Step 1 .31 .09**      
Negative 
Affectivity 
   .51 .13 .32** 4.03 
Step 2 .36 .13 .03     
DTS  
Absorption 
   -.47 .53 -.12 -.87 
DTS 
Appraisal 
   .02 .32 .01 .07 
DTS 
Regulation 
   -.46 .56 -.09 -.82 
DTS 
Tolerate 
   -.03 .43 -.09 -.82 
Notes: * = p <0.05; ** = p <0.01. DTS Absorption = Distress Tolerance Scale – Absorption Subscale 
(Simons & Gaher, 2005); DTS Appraisal = Distress Tolerance Scale – Appraisal Subscale (Simons & 
Gaher, 2005); DTS Regulation = Distress Tolerance Scale – Regulation Subscale (Simons & Gaher, 2005); 
DTS Tolerance = Distress Tolerance Scale – Tolerance Subscale (Simons & Gaher, 2005); Cannabis 
Withdrawal = Marijuana Withdrawal Checklist (Budney et al., 1999); Barriers to Cannabis Cessation = 




Table 11: Hierarchical regression models post hoc mediation models 




1 DTS NA (a) -.21 .05 -4.46 < .001 -.29 -.12 
 NA  MWC (b) .66 .17 3.77 < .001 .31 1.01 
 DTS   MWC (c’) -.14 .10 -1.30 .19 -.35 .07 
 NA  MWC (c) -.27 .10 -2.64 < .01 -.48 -.07 
 DTS   NA   MWC (a*b) -.14 .05   -.25 -.05 
2 DTS NA (a)       
 NA  SEQ (b) .52 .18 1.37 < .01 .16 .88 
 DTS   SEQ (c’) .15 .11 1.37 .17 -.07 .37 
 NA  SEQ (c) .04 .11 .40 .69 -.17 .25 
 DTS   NA   SEQ (a*b) -.11 .04   -.20 -.04 
3 DTS NA (a)       
 NA  BCCS (b) .43 .13 3.22 < .01 .16 .69 
 DTS   BCCS (c’) -.15 .08 -1.88 .06 -.31 .01 
 NA  BCCS (c) -.24 .08 -3.02 < .01 -.39 -.08 
 DTS   NA   BCCS (a*b) -.08 .03   -.17 -.03 
4 DTS NA (a)       
 NA  MPS (b) .00 .00 3.97 < .001 -.00 .01 
 DTS   MPS (c’) .00 .00 -.55 .58 -.00 .00 
 NA  MPS (c) .00 .00 1.94 .05 -.00 .00 
 DTS   NA   MPS (a*b) .00 .00   -.00 .00 
Notes: Path a is equal across all models; therefore, it is presented only in the model with Y1 to avoid 
redundancies. N for analyses of models Y1 included 152 cases, Y2 included 154 cases, Y3 included 150 
cases, and analyses for Y1 included 153 cases. The standard error and 95% CI for a*b are obtained by 
bootstrap with 10,000 re-samples. DTS (Distress Tolerance Scale Total Score; Simons & Gaher, 2005) is 
the independent variable (X), NA (Positive and Negative Affect Scale – Negative Affect subscale; Watson 
et al., 1988) is the mediator (M), and MWC ([Y1] Marijuana Withdrawal Checklist – Total Score; Budney 
et al., 1999), SEQ ([Y2] Self-Efficacy Questionnaire – Total Score; Marlatt & Gordon, 1985), BCCS ([Y3] 
Barriers to Cannabis Cessation Scale – Total Score), and MPS ([Y4] Marijuana Problems Scale Total Score; 
Stephens et al., 2000) are the outcome variables. CI (lower) = lower bound of a 95% confidence interval; 




































Notes: * = p < 0.05; ** = p < 0.01. NA = Positive and Negative Affect Scale – Negative Affect subscale 
(Watson et al., 1988); BHT= latency to end the 2nd trial of the breath holding task (Asmundson & Stein, 
1994); DTS = Distress Tolerance Scale – Total Score (Simons & Gaher, 2005); Fear of Detox = Detox Fear 
Survey Schedule-27 (Milby et al, 1987); MEAQ = Multidimensional Experiential Avoidance Questionnaire 
– Total Score (Gamez, Kotov, Ruggero, & Watson, 2011); ASI-III = Anxiety Sensitivity Index III –  Total 
Score (Taylor et al., 2007); DIS = Discomfort Intolerance Scale – Total Score (Schmidt et al., 2006); DERS 
= Difficulties in Emotion Regulation Scale – Total Score (Gratz & Roemer, 2004); AAQ = Acceptance and 
Action Questionnaire – Total Score (Hayes et al., 2004); MAAS = Mindful Awareness and Attention Scale 
– Total Score (Brown & Ryan, 2003); Life time Quit Index = total number of lifetime quit attempts; 
Longest Quit Dur. = duration in days of longest abstinence period ever achieved; Recent Quit Dur. = 
duration in days of most recent abstinence period; MWC = Marijuana Withdrawal Checklist – Total Score 
(Budney et al, 1999); SEQ = Self-Efficacy Questionnaire – Total Score (Marlatt & Gordon, 1985); BCCS = 
Barriers to Cannabis Cessation Scale – Total Score; MPS = Marijuana Problems Scale – Total Score 

















               



































              






             























































         
















        























































































   
14. SEQ 56.06(17.62) 





























16. MPS 27.06(6.96) 










































Notes: NA = data not reported in original journal article; * = author reported DTS total score. For 
comparison to the current study, the statistic can be divided by four (the number of subscales), to yield an 
approximate mean of 2.16; ** = author reported DTS total score by gender; first mean is for females; *** 
= authors employed a frequency mean using the following scale: 0 = never used in my life, to 6 = used 
more than 300 days; **** = authors employed a frequency mean using the following type scale, ranging 
from 0 to 8 (0 = no use in the past 30 days, 4 = use once or more per week, 8 = used more than once per 
day; ***** = authors used an ‘intensity’ scale, assessing average cannabis use during four possible time-
points, for each day of the week, for a 6-month period. 


























Daughters et al., 
2005 
(n = 89) 
39.2 
(9.4) 





Simons & Gaher, 
2005 













NA NA ***3.22 
(1.26) 
Buckner et al., 
2007 
(n = 89) 
18.7 
(1.2) 








NA RAPI 50.04 
(14.01) 
NA NA 8.2% 
Zvolensky et al., 
2009 
(n = 89) 
20.45 
(5.0) 








63% NA 67% 
Potter et al., 2011 








NA NA NA NA ****4.64 
Bujarski et al., 
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NA NA NA NA 100% 
Dvorak at al., 2014 










NA NA NA ***** 0.83 
(2.59) 
Current Sample 



























Notes: a = Effect of X on M; b = Effect of M on Yi; c’i = Direct effect of X on Yi controlling for M; a*b = 

















[Y1] MWC Total Score 
[Y2] SEQ Total Score 
[Y3] BCCS Total Score  










Appendix A: Description of additional post-hoc measures 
Detox Fear Survey Schedule-27 (DFSS-27; Gentile & Milby, 1992). The DFSS is a 27-item self-
report measurement of an individual’s level of fear related to physical, emotional, and social consequences 
of withdrawal, which exacerbate the experience of withdrawal process leading to more failed detoxification 
attempts (Gentile & Milby, 1992). The measure assesses fear of detoxification on a five-point likert-type 
scale, ranging from 0 (not disturbed at all) to 4 (very much disturbed). The DFSS-27 was created to assess 
for pathological phobia of opioid detoxification (sample item: scared of becoming re-addicted), which was 
revised by Milby et al. (1987) to include a semi-structured interview, which was not employed for the 
current study. In the current investigation, for the scope of the current project, all self-report items that were 
directly relevant only to opioid detoxification were removed (e.g., “being told at the nursing station you 
have almost completed detox”), resulting in 20 remaining items that were general to all substance use.  
Internal consistency for the DFSS in the present study was excellent (α = .93).  
Multidimensional Experiential Avoidance Questionnaire (MEAQ; Gamez et al., 2011). The 
MEAQ is a 62-item measure of experiential avoidance. Items are rated from 1 (strongly disagree) to 6 
(strongly agree). The MEAQ consists of six subscales: (1) Distress Aversion; (2) Behavioral Avoidance; 
(3) Distraction and Suppression; (4) Repression and Denial; (5) Procrastination; and (6) Distress 
Endurance. The summed responses yield a total score, consisting of all sub-scale items. The MEAQ 
demonstrates convergence with other measures of experiential avoidance (Gamez et al., 2011). In the 
present sample, internal consistency was adequate for the global MEAQ total score (α=.95).   
Anxiety Sensitivity Index-3 (ASI-3; Taylor et al., 2007). The ASI-3 is an 18-item self-report 
measure that assess the degree to which a respondents fears the potential negative consequences of anxiety-
related symptoms and sensations (sample item: “It scares me when my heart beats fast”) on a 5-point 
Likert-type scale from 0 (very little) to 4 (very much). In the current investigation, the ASI-3 had excellent 
internal consistency (α = .92).  
 88 
 
Discomfort Intolerance Scale (DIS; Schmidt et al., 2006). The DIS is a 5-item self-report measure 
that assesses the degree to which a respondent agrees with statements related to their perceived intolerance 
of physical distress or discomfort (sample item: “I take extreme measures to avoid feeling physically 
uncomfortable”) on a 7-point Likert-type scale from 0 (not at all like me) to 6 (extremely like me). The DIS 
has demonstrated consistent psychometric properties as observed in past work (see Schmidt et al., 2006). 
Internal consistency for the DIS in the present study was adequate (α = .79).   
Difficulties in Emotional Regulation Scale (DERS; Gratz & Roemer, 2004). The DERS is a 36-
item assessment of emotion dysregulation. Items are rated from 1 (almost never) to 5 (almost always). In 
the current investigation, the DERS total sum score was used. Consistent with past work (Gratz & Roemer, 
2004), the scale demonstrated excellent adequate internal consistency in the current sample (α=.92).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
